



**Vaccines and Global Health: The Week in Review**  
**27 August 2021 :: Issue 618**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 23,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS  
Editor and  
Executive Director  
Center for Vaccine Ethics & Policy  
[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).

***Support this knowledge-sharing service:*** Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.

**Contents** [click on link below to move to associated content]

- A. Milestones :: Perspectives :: Featured Journal Content
- B. Emergencies
- C. [WHO; CDC \[U.S., Africa, China\]](#)
- D. [Announcements](#)
- E. [Journal Watch](#)
- F. [Media Watch](#)

***Vaccines and Global Health : The Week in Review resumes publication with this edition of 7 August 2021 following a brief leave for the Editor.***

:::::  
:::::

**WHO Director-General's opening remarks at the Member State Information Session on COVID-19 - 5 August 2021**

5 August 2021

Honourable Ministers, Excellencies, dear colleagues and friends,  
Good morning, good afternoon and good evening to all Member States, and thank you for joining us once again in our weekly session.

With the development of vaccines in record time we have come so far. But the world is now in a period of real danger. Many of the gains we have made are now being eroded.

The total number of reported cases will likely pass 200 million tomorrow. And we know the real figures are much higher. **The highly transmissible Delta variant has now been detected in at least 132 countries. But the rise in cases is not just a natural process; it is being fuelled by increased social mixing, inconsistent public health and social measures, and inequitable vaccination.**

Over 4 billion vaccines have been administered globally, but more than 80% have gone to high- and upper-middle income countries. **Health workers and people most at risk in lower-income countries are not receiving vaccines, while some countries are vaccinating those at low risk of serious disease.**

This is wrong. The hard-won gains we have made are being lost, and health systems in many countries are being overwhelmed as the increased number of infections is creating a shortage of life-saving treatments.

Twenty-nine countries have high and rising oxygen needs, and many countries have inadequate supplies of basic equipment to protect frontline health workers. Meanwhile, testing rates in low-income countries are less than 2% of what they are in high-income countries. This leaves us blind to understanding where the disease is and whether new, more dangerous variants are emerging.

So far, the Secretariat has supported 117 countries with oxygen concentrators and generators; we're providing guidance to help countries better detect variants; and we continue to work daily with our global networks of experts to understand why the Delta variant spreads so readily. But the needs are much greater than the resources we have to meet them.

**The WHO Strategic Preparedness and Response Plan for 2021 faces a funding shortfall of US\$900 million, almost half of what we need.** Of the funds we have received, nearly all of them are earmarked. This shortfall is already having an impact on our operations, and the lack of flexibility, in particular, leaves us in real danger of not being able to sustain urgent priorities for vaccination, surveillance and response in countries experiencing surges in cases.

In addition, the Access to COVID-19 Tools Accelerator is launching the Rapid ACT-Accelerator Delta Response, or RADAR, issuing an urgent call for US\$7.7 billion for tests, treatments and vaccines. In

parallel, we will need \$3.8 billion in additional financing this year for COVAX to exercise its options to purchase vaccines for 2022.

At the same time, we are working to find new ways of scaling up vaccine production. Last week we took another step forward in setting up a technology transfer hub for mRNA vaccines in South Africa, with a letter of intent that sets out the terms of collaboration.

**WHO's goal remains to support every country to vaccinate at least 10% of its population by the end of September and at least 40% by the end of this year, and 70% of the world's population by the middle of next year.**

Yet even while a large percentage of the world's people are still waiting for their first dose, some countries are moving towards booster doses. I understand the concern of all governments to protect their people from the Delta variant. **But we cannot accept countries that have already used most of the global supply of vaccines using even more of it, while the world's most vulnerable people remain unprotected.**

High-income countries have now administered almost 100 doses for every 100 people. Meanwhile, low-income countries have only been able to administer 1.5 doses for every 100 people, due to lack of supply.

**We need an urgent reversal, from the majority of vaccines going to high-income countries, to the majority going to low-income countries. That's why I am calling for a moratorium on boosters until at least the end of September, to enable at least 10% of the population of every country to be vaccinated.**

To make that happen, we need everyone's cooperation, especially the handful of countries and companies that control the global supply of vaccines. **We call on those countries and vaccine producers to prioritize COVAX.**

At the same time, we must all remember that vaccines are not the only tool. Indeed, there is no single tool that will defeat this pandemic. We can only defeat it with a comprehensive approach of vaccines in combination with the proven public health and social measures that we know work.

:::::

:::::

**The Independent Panel for Pandemic Preparedness and Response**  
**Elevating political leadership for Pandemic Preparedness and Response Meeting with the UN General Assembly**

28 July 2021

*Statement [Excerpts]*

**Ellen Johnson Sirleaf**

...So today there is a choice – to carry on with business as usual with the inevitability of a future pandemic catastrophe, or to make real and lasting change.

That choice is clear: now we must act - **this must be the last pandemic to cause devastation on the scale we are witnessing today. We need a stronger international system for pandemic**

**preparedness and response that understands the threats, is alert, and is poised to take collective action.** The job can't be done by any single country working alone. It can't even be done by a group of countries, no matter how willing, because we are only as strong as our weakest link. Therefore, **the UN General Assembly has a decisive role to play in strengthening the multilateral infrastructure** so that it can identify and respond more quickly to the next virus with pandemic potential.

### **Helen Clark**

...The international system needs to work as a coherent and effective system – and it must also work across sectors and silos. The pandemic is not only a health crisis; it is also a social economic, political, and peace and security crisis. That is why we have come to you – the UN General Assembly. Our Panel believes that the General Assembly has a crucial role to play in ensuring that the international system is co-ordinated and empowered to identify and act against future diseases with pandemic potential. We said earlier that our recommendations are a package. **We propose that a negotiated political declaration be adopted by the UN General Assembly later this year, setting out the road map for a stronger international system for the future.**

That roadmap should set out the architecture required and the steps to be taken to create it. It should encompass support for a new high-level oversight council, a dedicated financing mechanism, a new pandemic convention, and a redesigned, permanent mechanism replacing ACT-A based on a global public goods model.

**At the top of that system, our Panel recommends the creation of a Global Health Threats Council** at the level of Heads of State and Government and including private sector and civil society representation. Pandemic preparedness must be led from the top, and it must be multisectoral.

Indeed, that Council would be tasked with maintaining political commitment to pandemic preparedness and response. It would not be an operational body, but rather a body that monitors progress, draws attention to gaps, **and holds actors accountable** – all key functions that the Panel found were missing in the international system.

WHO has an indispensable role in responding to global health emergencies and ensuring longer-term public health and health security through the strengthening of primary health systems in all countries. **WHO is and should remain the lead agency for health in the international system.** The quality, timing, and clarity of the technical advice and direction WHO provides to the world are of the utmost importance and Member States must adequately resource, empower, and further strengthen it. We welcome the initiative taken by the World Health Assembly to establish a Working Group on strengthening WHO.

The Panel backs the calls for a new pandemic framework convention which should, among other things, fill gaps in the current legal system and clarify the responsibilities between States and international actors. This pandemic treaty or framework convention would give state parties the opportunity to commit to the principles of pandemic preparedness and response in the spirit of mutual obligation, and give a framework for the institutional architecture needed to prevent future pandemics.

**The Panel recommended that it be adopted using the powers under Article 19 of the WHO Constitution, and be complementary to the International Health Regulations.**

**We propose the creation of an international pandemic financing facility.** It must be able distribute up to ten billion dollars a year for preparedness and disburse up to one hundred billion in the event of a crisis. Ultimately, investing billions in preparedness now will save trillions in the future, as the current pandemic has so clearly illustrated. Funding for response to this pandemic generally was too little and came too late.

The facility should raise resources on an ability-to-pay formula with all countries contributing and allocations being made to those requiring solidarity funding. This should be a sustainable core commitment - not subtracted from an already stretched development assistance envelope. The facility could be hosted by an existing institution which is representative of countries big and small, rich and poor – we have proposed that the Global Health Threats Council be the allocator of funds.

**The Panel considered that the current model of development and delivery of vaccines, diagnostics, and therapeutics for pandemics is not fit for purpose.** We believe there is a need to shift away from a market-based model to one based on global public goods. This can be achieved through a transformation of ACT-A.

**The Panel has recommended increasing the authority and independence of WHO,** including by it having adequate, predictable, flexible and sustainable funding, and having its Director General and Regional Directors in future each serving a single term of seven years.

A greatly improved system for disease surveillance and alert is needed. WHO must have the authority to investigate outbreaks of concern rapidly, and publish information rapidly on its own authority. Future declarations of a Public Health Emergency of International Concern by the WHO Director-General should be based on the precautionary principle where warranted, as in the case of respiratory infections. **PHEIC declarations should be based on clear, objective, and published criteria.**

The Panel recommended that WHO set measurable benchmarks for country preparedness and response capacities, and for countries to invest accordingly, with support coming from the dedicated financing mechanism for those with limited resources. **WHO should formalise universal periodic peer reviews of country progress against the benchmarks** it sets. We also brought the IMF into the picture – proposing that it incorporate assessments of preparedness as part of its Article Four consultations.

Ultimately preparedness rests on national governments setting up the right structures, developing the needed capacities, and investing in vital assets such as health and other system resilience and social protection. Governments can listen and learn from the best practices we illustrate in our report.

### **Ellen Johnson Sirleaf**

...I speak with conviction when I say that this current pandemic must be the last to cause devastation to human life, societies, and economies. As a world, we must do better.

This time we must act and not bury this analysis and these recommendations in the vault as has happen many times before.

To implement a package of reforms like that which our Panel has developed will require the engagement of Heads of State and Government. Every Head of State and Government is currently focused on the problems created by the pandemic.

It is vital now to mobilise the political will to make the changes required for a more effective and timely global response next time a pandemic threat emerges. We owe this to future generations.

**The General Assembly has the authority to convene at the highest level to endorse a negotiated political declaration which will drive reform.** That is what our Panel has requested the General Assembly to do, and we hope that you will give this your most serious consideration.

:::::

:::::

**Joint Statement of the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics, and Diagnostics for Developing Countries following its Second Meeting**

*New Global Database to Enhance Transparency and Improve Delivery of COVID-19 Tools*

WASHINGTON, July 30, 2021 — The Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries, established by the heads of the **International Monetary Fund, World Bank Group, World Health Organization and the World Trade Organization** to identify and resolve finance and trade impediments to vaccine, diagnostics, therapeutic production and deliveries, today launched a [new website](#) that includes the first phase of a global database and country dashboards on vaccines, therapeutics, and diagnostics to guide their work and advocacy. It also today issued the following joint statement:

**"We reiterate the urgency of providing access to COVID-19 vaccines, tests and treatments to people throughout the developing world. In the area of vaccines, a key constraint is the acute and alarming shortage in the supply of doses to low and low-middle income countries, especially for the rest of 2021.** We call on countries with advanced COVID-19 vaccination programs to release as soon as possible as much of their contracted vaccine doses and options as possible to COVAX, AVAT, and low and low-middle income countries.

We are concerned that vaccine delivery schedules and contracts for COVAX, AVAT, and low and low-middle income countries are delayed or too slow. **Less than 5% of vaccine doses that were pre-purchased by or for low-income countries have been delivered.** Our common target is for at least 40% of people in low and low-middle income countries to be vaccinated by the end of 2021. We estimate that less than 20% of the necessary vaccines is currently scheduled for delivery to these countries, whether through COVAX, AVAT, or bilateral deals and dose-sharing agreements.

**We urge COVID-19 vaccine manufacturers to redouble their efforts to scale up production of vaccines specifically for these countries,** and to ensure that the supply of doses to COVAX and low and low-middle income countries takes precedence over the promotion of boosters and other activities. We call on governments to reduce or eliminate barriers to the export of vaccines and all materials involved in their production and deployment. We underscore the urgent need for all parties to address supply chain and trade bottlenecks for vaccines, testing, and therapeutics as well as all of the materials involved in their production and deployment.

As per the IMF staff's \$50 billion proposal to end the pandemic, and in line with the priorities set out by WHO, WTO, IMF and the World Bank Group, **over \$35 billion in grant are needed with only one third of this financed to date.** We welcome the recent announcement by COVAX and the World

Bank to accelerate vaccine supplies for developing countries through a new financing mechanism. We also welcome the partnership between the World Bank and AVAT, noting that World Bank financing is now available to support the purchase and deployment of doses secured by both AVAT and COVAX.

**It is critical to improve clarity and transparency around the evolving vaccine market, expected production volumes, delivery schedules, and pre-purchase options.** We call on manufacturers to accelerate delivery to developing countries and we call on advanced economies to scale-up near-term deliveries to developing countries."


The database and country-by-country dashboards, which also build on the IMF-WHO COVID-19 Vaccine Supply [Tracker](#), seek to focus international attention and mobilize action by illuminating specific gaps, not just globally but also country-by-country.

### **[TASK FORCE ON COVID-19 VACCINES, THERAPEUTICS, AND DIAGNOSTICS](#)**

International Monetary Fund, World Bank Group, World Health Organization, World Trade Organization

Through this web site, which includes a global database and country-by-country data dashboards, the Task Force is tracking and monitoring specific global and country-level gaps to support faster and more targeted solutions to accelerate access to COVID-19 vaccines, treatments and tests in developing countries. [Read more on the purpose of this website and how to explore the data](#)

Website accessed 7 Aug 2021: <https://data.covid19taskforce.com/data>



### **Featured Journal Content**

National Academy of Medicine – *NAM Perspectives Discussion Paper*

#### **[Biomedical Research COVID-19 Impact Assessment: Lessons Learned and Compelling Needs](#)**

By Nakela L. Cook and Michael S. Lauer  
July 26, 2021 | Discussion Paper :: 28 pages

NAM Perspectives. Discussion Paper, National Academy of Medicine, Washington, DC. <https://doi.org/10.31478/202107e>.

Open Access PDF: <https://nam.edu/wp-content/uploads/2021/07/Biomedical-Research-COVID19-Impact-Assessment.pdf>

### ***Introduction***

The COVID-19 pandemic, a public health emergency of unprecedented scale and consequences, has revealed vulnerabilities in our health care system and public health infrastructure, yet also serves as a remarkable learning opportunity for transformational changes. **Effects of the COVID-19 pandemic touch every aspect of life in ways not previously imagined—the biomedical and health research enterprises are no exception.** Preexisting stresses in the research sector's workforce, processes, and organizations have been exacerbated in the sector's quest to effectively generate meaningful information in response to the pandemic and deliver research in new and innovative ways.

**The COVID-19 pandemic revealed the necessity to enhance the ability for researchers to share data through interoperable and customizable systems to enable rigor, reproducibility, and efficiency. This properly stewarded data essential for research is available and actionable, but trust remains a critical issue in establishing and maintaining data sharing entities [147].**

Despite the rapid innovation occurring during the COVID-19 pandemic, longstanding problems remain. The disproportionate burden of COVID-19 cases and outcomes amongst lower-income populations and communities of color underscores the need to address the lack of diversity of clinical research participants as a top priority. **The type of causal, clinical, and population-related intervention studies that may have a critical impact on outcomes in this pandemic necessitated the inclusion of a large, diverse pool of participants most adversely affected and traditionally underrepresented in research.**

Government funding focused on community engagement in research can certainly be a lever to promote diversity in study participation, as regulatory bodies seek to ensure the safety and efficacy of therapies across diverse populations [151]. **This paper describes the current status of research and the challenges, lessons learned, and the potential, if the challenges are overcome, for a longer-term impact beyond the pandemic to enhance the resilience and diversity of the biomedical research workforce.** These lessons learned can also be applied to help advance the rapid translation of research into practice (from basic science to clinical and population settings to applied public health), promote the sharing of data for delivering near real-time results in a clinical setting, and elevate community and participants as equal partners in research...

### ***Summary and Priorities***

#### ***Assessing the Impact***

**The COVID-19 pandemic will have long-standing implications for the research enterprise, which may not return to pre-pandemic operations.** A critical priority over the next 6–12 months will be to assess, in both quantitative and qualitative terms, the ongoing and longer-term impact of the pandemic, including opportunities for research to continue to help mitigate and overcome the pandemic, ensuring the future of the research enterprise is protected, and learning and transforming research to capitalize on lessons from the pandemic response. The Council on Governmental Relations posted a working paper in August 2020 describing a Research Impact Metric by which institutions can assess their operations. The working paper describes a new “Pandemic Normal” characterized by

ongoing slow-downs, changes in operations (e.g., shift work, required protective equipment), supply challenges, core facility disruptions, slowed hiring and promotion, and perhaps above all, a great deal of uncertainty [36]. A recently published landscape review described some of the uncertainties: the trajectory of federal funds and policies, the role of charitable foundations, the impact of declines in non-research revenues on research operations, whether future shut-downs may be needed as the pandemic worsens, what the long-term effects on research collaborations (positive and negative) will be, how changes in rapid scientific communication and peer review will evolve, whether research will return to “normal” levels of productivity and on what timeline, and what will happen to the scientific workforce [140]...

### ***Research Participants and Public Participation in Research***

This pandemic has created an imperative for communication, collaboration, and coordination across sectors that could not be stronger. Actions and considerations include the following:

- :: The establishment of meaningful partnerships and trust with affected communities as research partners is central to the path forward to combat high levels of distrust of scientists and researchers.** Partnerships begin with the identification and involvement of community brokers and subsequently identified community entities in understanding the purpose of research studies, setting research priorities, and translating information to communities.
- :: Engagement of stakeholders, patients, and communities leveraging community brokers toward building trust and trustworthiness and enhancing diverse participation in research.**
- :: Broad scientific communications enhance the value of research conveyed to the public and build trust among individuals, organizations, and broader communities.**

In the face of unprecedented challenges and urgent necessity, the biomedical and health research enterprise has the potential to deliver the discovery, translation, and implementation science related to vaccines and therapeutics required to end the COVID-19 pandemic. To propel the entire sector toward a holistic approach, it is crucial that all components of the research ecosystem collaborate on a multifaceted transformation that enhances the resilience and diversity of the research workforce and innovates in funding processes and partnerships to maintain the viability of research efforts during a crisis. **The research sector of the future accelerates the translation of knowledge to care and public health action, delivers on long-standing data sharing efforts, and coordinates across health and health care. Essential to the sector’s efforts to innovate and achieve is the elevation of communities and participants as equal partners in research while engaging the public in science.**

::::::  
::::::

### **COVID**

#### ***Editor’s Note:***

As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive, If you recognize a missed strategic development, a new source of rigorous

analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition:  
[david.r.curry@ge2p2global.org](mailto:david.r.curry@ge2p2global.org)

**We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon.** We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

:::::

:::::

## **COVID Vaccines – OCHA:: HDX**

### **COVID-19 Data Explorer: Global Humanitarian Operations**

#### ***COVID-19 Vaccine Roll-out***

**Aug 07, 2021** | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | [DATA](#)

**Global COVID-19 Figures: 201M total confirmed cases; 4.3M total confirmed deaths**

**Global vaccines administered: 4.40B**

Number of Countries: 26 [26]

COVAX Delivered (Number of Doses): 44M

Other Delivered (Number of Doses): 57M

Total Delivered (Number of Doses): 100M

Total Administered (Number of Doses): 96M

:::::

:::::

## **Coronavirus [COVID-19] - WHO**

*Public Health Emergency of International Concern (PHEIC)*

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### ***Weekly Epidemiological and Operational updates***

*Last update: 2 Jul 2021*

**Confirmed cases ::** 200 840 180

**Confirmed deaths ::** 4 265 903

**Vaccine doses administered:** 3 984 596 440

:::::

:::::

### **Weekly operational update on COVID-19 - 4 August 2021**

#### *Overview*

In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

- Supporting COVID-19 emergency preparedness and response in Thailand
- Supporting treatment of COVID-19 patients across Yemen

- Facilitating the implementation of Single Nucleotide Polymorphism (SNP) assays to detect SARS-CoV-2 variants in Ukraine
- More than one million COVID-19 vaccines arrive in Lao People's Democratic Republic through the COVAX Facility
- Driving COVID-19 vaccine uptake in Ghana's hard-to-reach communities
- Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
- Updates on WHO's financing to support countries in SPRP 2021 implementation and provision of critical supplies.

### **Weekly epidemiological update on COVID-19 - 3 August 2021**

#### *Overview*

Globally, weekly cases have been increasing for more than a month, with over 4 million cases reported in the past week. An average of over 570 000 cases were reported each day over the past week as compared to a little over 540 000 cases reported daily the week before. This increasing trend is largely attributed to substantial increases in the Eastern Mediterranean and the Western Pacific Regions which reported a 37% and 33% increase respectively as compared to the previous week. Overall, the number of deaths reported this week decreased by 8% as compared to the previous week, with over 64 000 deaths reported. However, the Western Pacific Region and the Eastern Mediterranean Region showed a sharp increase in new deaths as compared to the previous week, 48% and 31% respectively. The cumulative number of cases reported globally is now nearly 197 million and the number of cumulative deaths has reached 4.2 million.

In this edition, a special focus updates are provided on:

- SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta which includes updates on the geographic distribution of VOCs.
- 
- 
- 

### **Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 15 July 2021**

For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date

*[No update since 15 July 2021; click on the link above for full scale view]*

▪▪▪▪  
▪▪▪▪▪

**COVID Vaccine Developer/Manufacturer Announcements** *[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]*

#### **AstraZeneca**

*Press Releases* •

**[Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people](#)**

28 July 2021

**Vaxzevria showed no increased incidence of thrombosis with thrombocytopenia after second dose**

28 July 2021

**BioCubaFarma** – Cuba

Últimas Noticias

[Website not responding at inquiry; receiving 403=Forbidden message]]

**CanSinoBIO**

News - No new digest announcements identified

**Clover Biopharmaceuticals** - China

News - No new digest announcements identified

**Curevac [Bayer Ag – Germany]**

News - No new digest announcements identified

**Gamaleya National Center**

Latest News and Events - No new digest announcements identified [See Russia/RFID below]

**IMBCAMS**, China

Home - No new digest announcements identified

**Janssen/JNJ**

Press Releases

Jul 29, 2021

**Johnson & Johnson Statement on U.S. FDA Approval of Shelf Life Extension for Company's COVID-19 Vaccine**

**Moderna**

Press Releases

August 3, 2021

**Moderna Receives FDA Fast Track Designation for Respiratory Syncytial Virus (RSV) Vaccine (mRNA-1345)**

August 2, 2021

**Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic**

**Novavax**

Press Releases

**Novavax Announces COVID-19 Vaccine Booster Data Demonstrating Four-Fold Increase in Neutralizing Antibody Levels Versus Peak Responses After Primary Vaccination**

Aug 5, 2021

**Novavax and Serum Institute of India Announce Submission to Regulatory Agencies in India, Indonesia, Philippines for Emergency Use Authorization of Novavax' Recombinant Nanoparticle COVID-19 Vaccine**

Aug 5, 2021

## **[Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine](#)**

Aug 4, 2021

### **Pfizer**

[Recent Press Releases](#) - No new digest announcements identified

### **Sanofi Pasteur**

[Press Releases](#)

August 03 2021 Press releases

### **[Sanofi to acquire Translate Bio; advances deployment of mRNA technology across vaccines and therapeutics development](#)**

- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas
- Fast tracks establishment of Sanofi's recently announced mRNA Center of Excellence
- Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology

PARIS and LEXINGTON, Mass – August 3, 2021 – As part of Sanofi's endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for \$38.00 per share in cash, which represents a total equity value of approximately \$3.2 billion (on a fully diluted basis). The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction...

### **Serum Institute of India**

[NEWS & ANNOUNCEMENTS](#) - No corporate announcements identified

[Last media release still posted is dated February 15, 2021; media release of April 21, 2021 apparently removed]

### **Sinopharm/WIBPBIBP**

[News](#) - No new digest announcements identified

### **Sinovac**

[Press Releases](#)

### **[SINOVAC Announces Positive Data on Booster Dose of CoronaVac®](#)**

021/07/21

### **Vector State Research Centre of Virology and Biotechnology**

[Home](#) - No new digest announcements identified

### **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

[No website identified]

::::::

## GSK

Press releases for media

28 July 2021

### **GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab**

GlaxoSmithKline plc and Vir Biotechnology, Inc. announce the supply of 220,000 doses of sotrovimab for adults and adolescents with COVID-19.

26 July 2021

### **Shingrix approved in the US for prevention of shingles in immunocompromised adults**

Immunocompromised individuals are at greater risk of shingles and associated complications than immunocompetent individuals

## SK Biosciences

Press releases - No new digest announcements identified

::::::

::::::

### **UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 7 Aug 2021**

**An overview of information collected from publicly announced bilateral and multilateral supply agreements [agreements view since last week's edition]**



**22**

vaccines approved for use by at least one national regulatory authority<sup>1</sup>



**7**

vaccines in WHO's Emergency Use Listing



**18.3bn**

doses secured globally



**\$2 - \$37**

reported vaccine price range per dose



**5.09bn**

doses COVAX has secured, optioned, or received as donations



**189.9M**

doses shipped through COVAX to 138 countries

Deal date	Recipient	Deal type	Vaccine name	Vaccine developer	Manufacturer
7/12/2021	Taiwan	Private Purchase	Pfizer BioNTech		Fosun Pharma
7/12/2021	Viet Nam	Bilateral	Gamaleya Research Institute		Gamaleya Research Institute
7/13/2021	Viet Nam	Bilateral	Bharat Biotech		Bharat Biotech
7/14/2021	Bangladesh	Bilateral	Sinopharm (Beijing)		Sinopharm (Beijing)
7/14/2021	Viet Nam	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
7/15/2021	India	Bilateral	Bharat Biotech		Bharat Biotech
7/15/2021	India	Bilateral	Serum Institute of India		Serum Institute of India
7/16/2021	Namibia	Bilateral	Sinopharm (Beijing)		Sinopharm (Beijing)
7/19/2021	Malaysia	Bilateral	Sinovac		Pharmaniaga
7/20/2021	Cambodia	Bilateral	Sinopharm (Beijing)		Sinopharm (Beijing)
7/20/2021	Japan	Bilateral	Moderna		Moderna
7/20/2021	Peru	Bilateral	Gamaleya Research Institute		Gamaleya Research Institute
7/21/2021	Taiwan	Private Purchase	Pfizer BioNTech		Fosun Pharma
7/22/2021	Taiwan	Bilateral	Moderna		Moderna
7/23/2021	USA	Bilateral	Pfizer BioNTech		Pfizer/BioNTech
7/24/2021	Paraguay	Bilateral	Moderna		Moderna
7/26/2021	Belarus	Bilateral	Sinopharm (Beijing)		Sinopharm (Beijing)

::::::

::::::

## World Bank Vaccine Operations Portal

<https://www.worldbank.org/en/who-we-are/news/coronavirus-covid19/world-bank-support-for-country-access-to-covid-19-vaccines>

*As of July 29, 2021, the World Bank approved operations to support vaccine rollout in 54 countries amounting to \$4.6 billion. See the latest project financing, project documents and procurement information in the list below:*

### **Countries receiving World Bank support for vaccines**

As of July 29, 2021

*This list of countries, project documents, and procurement notices and contracts will be updated as data becomes available.*

::::::

::::::

## Duke – Launch and Scale Speedometer

### **The Race for Global COVID-19 Vaccine Equity**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables

and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution  
[accessed 24 July 2021]

[See our COVID Vaccine Purchases research](#)

[See our COVID Vaccine Manufacturing research](#)

[See our COVID Vaccine Donations & Exports research](#)


:::::  
:::::

### **Global Dashboard on COVID-19 Vaccine Equity**

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

**Dashboard [accessed 07 Aug 2021]: <https://data.undp.org/vaccine-equity/>**






### ***Our World in Data***

#### **Coronavirus (COVID-19) Vaccinations** [Accessed 7 Aug 2021]

- 29.7% of the world population has received at least one dose of a COVID-19 vaccine, and 15.3% is fully vaccinated.
- 4.4 billion doses have been administered globally, and 40.04 million are now administered each day.
- Only 1.1% of people in low-income countries have received at least one dose.

Daily COVID-19 vaccine doses administered per 100 people, Aug 6, 2021  
 Shown is the rolling 7-day average per 100 people in the total population. For vaccines that require multiple doses, each individual dose is counted.

Our World  
in Data



Source: Official data collated by Our World in Data – Last updated 7 August 2021, 09:00 (London time)

[OurWorldInData.org/coronavirus](https://OurWorldInData.org/coronavirus) • CC BY


► Dec 3, 2020

Aug 6, 2021

COVID-19 vaccine doses administered per 100 people, Aug 6, 2021

For vaccines that require multiple doses, each individual dose is counted. As the same person may receive more than one dose, the number of doses per 100 people can be higher than 100.

Our World  
in Data



Source: Official data collated by Our World in Data – Last updated 7 August 2021, 09:00 (London time)  
[OurWorldInData.org/coronavirus](https://OurWorldInData.org/coronavirus) • CC BY

► Dec 2, 2020


Aug 6, 2021

## Share of the population fully vaccinated against COVID-19, Aug 6, 2021

Our World  
in Data

Total number of people who received all doses prescribed by the vaccination protocol, divided by the total population of the country.

[+ Add country](#)



Source: Official data collated by Our World in Data – Last updated 7 August 2021, 09:00 (London time)

Note: This data is only available for countries which report the breakdown of doses administered by first and second doses. Alternative definitions of a full vaccination, e.g. having been infected with SARS-CoV-2 and having 1 dose of a 2-dose protocol, are ignored to maximize comparability between countries.

OurWorldInData.org/coronavirus • CC BY

► Dec 27, 2020

Aug 6, 2021



## U.S.: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

### Vaccines and Related Biological Products Advisory Committee

:: No meetings scheduled



### White House [U.S.]

Briefing Room – Selected Major COVID Announcements

### Press Briefing by White House COVID-19 Response Team and Public Health Officials

August 05, 2021 • Press Briefings

### Remarks by President Biden on Fighting the COVID-19 Pandemic

August 03, 2021 • Speeches and Remarks

### FACT SHEET: President Biden Announces Major Milestone in Administration's Global Vaccination Efforts: More Than 100 Million U.S. COVID-19 Vaccine Doses Donated and Shipped Abroad

August 03, 2021 • Statements and Releases

## Press Briefing by White House COVID-19 Response Team and Public Health Officials

August 02, 2021 • Press Briefings

::::::

::::::

### **Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

#### **European Medicines Agency**

*News & Press Releases*

##### [News: ECDC and EMA update on COVID-19 \(new\)](#)

Last updated: 04/08/2021

*Full vaccination is key to protecting against serious COVID-19, including disease caused by the Delta variant*

With the increasing circulation of the Delta variant of SARS-CoV-2 in EU/EEA countries, the European Medicines Agency (EMA) and the European Centre for Disease Prevention and Control (ECDC) strongly encourage those who are eligible for vaccination but have not yet been vaccinated to start and complete the recommended COVID-19 vaccination schedule in a timely manner...

##### [News: Increased manufacturing capacity and supply for Spikevax \(new\)](#)

CHMP, Last updated: 30/07/2021

::::::

#### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*Latest Updates*


*News*

##### [ECDC and EMA update on COVID-19](#)


News story 4 Aug 2021

*Full vaccination is key to protecting against serious COVID-19, including disease caused by the Delta variant.*

::::::



### Total doses administered in EU/EEA countries



		EU	EU/EEA
Cumulative uptake of at least one dose among adults (18+) in EU/EEA	Cumulative uptake of full vaccination among adults (18+) in EU/EEA		
72.3%	60.4%		
Number of adults (18+) with at least one dose in EU/EEA		Number of full vaccinations among adults (18+) in EU/EEA	
267,920,314		223,838,012	

*Data as of 2021-08-07*

<https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab>

::::::

### European Commission

<https://ec.europa.eu/commission/presscorner/home/en>

Press release 4 August 2021

### [\*\*Coronavirus: Commission approves new contract for a potential COVID-19 vaccine with Novavax\*\*](#)

Today, the European Commission has approved its seventh Advanced Purchase Agreement (APA) with a pharmaceutical company to ensure access to a potential vaccine against COVID-19 in Q4 of 2021 and in 2022.

Press release 4 August 2021

### [\*\*Lebanon: EU mobilises €5.5 million for coronavirus response\*\*](#)

The Commission is allocating €5.5 million in humanitarian funding to help strengthen the COVID-19 response in Lebanon. The funding comes as Lebanon faces high infection rates, with the national health system close to collapse as well as low vaccination rates.

Statement 27 July 2021

### [\*\*Statement by President von der Leyen on a new milestone in the EU Vaccines Strategy\*\*](#)

President von der Leyen announced that the EU has achieved its goal of vaccinating 70% of its adult population with at least one dose in July.

::::::

::::::

### **Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**



# Africa CDC Vaccine Dashboard

## Africa Vaccinated

Vaccine Administered (Total) (68.21% of supply)

Vaccine Administered (1 Dose) (3.71% of population)

Vaccine Administered (2 Doses) (1.56% of population)

Vaccination Completed (1.58% of population)

Vaccines received from COVAX

**47**  
Countries

Vaccines received bilaterally

**42**  
Countries

Vaccines received from AVATT

**13**  
Countries

Current at 21 Jul 2021; Full scale, interactive dashboard available at: <https://africacdc.org/covid-19-vaccination/>

:::::

### **Africa announces the rollout of 400m vaccine doses to the African Union Member States and the Caribbean**

ADDIS ABABA, 5 August, 2021 – His Excellency President Cyril Ramaphosa, President of the Republic of South Africa and African Union (AU) COVID-19 Champion, is pleased to announce the start of monthly shipments of vaccines acquired by the AU / African Vaccine Acquisition Trust (AVAT) to the AU Member States today. An initiative by the AU Member States to pool their purchasing power, **the AVAT, on 28 March 2021, had signed the historic agreement for the purchase of 220 million doses of the Johnson & Johnson single-shot COVID-19 vaccine, with the potential to order an additional 180 million doses.** The Johnson & Johnson vaccine was selected for this first pooled procurement for three reasons: first of all, as a single-shot vaccine, it is easier and cheaper to administer; second, the vaccine has a long shelf-life and favourable storage conditions. Last but not least, the vaccine is partly manufactured on the African continent, with fill-finish activities taking place in South Africa.

President Ramaphosa said: "This is a momentous step forward in Africa's efforts to safeguard the health and well-being of its people. By working together and by pooling resources, African countries have been able to secure millions of vaccine doses produced right here in Africa. This will provide impetus to the fight against COVID-19 across the continent and will lay the basis for Africa's social and economic recovery."...

...This vaccine acquisition is a unique milestone for the African continent. It is the first time Africa has undertaken a procurement of this magnitude involving all Member States. **It also marks the first time that the AU Member States have collectively purchased vaccines to safeguard the health of the African population** – 400m vaccines are sufficient to immunise a third of the African

people and bring Africa halfway towards its continental goal of vaccinating at least 60 per cent of the population. International donors have committed to deliver the remaining half of the doses required through the COVAX initiative.

It is significant that **these vaccine doses are being produced on the African continent at the Aspen Pharmacare facility in Gqeberha in South Africa**. This is part of the concerted effort by African countries to rally the world to support the TRIPS waiver for technology transfer and active pharmaceutical ingredients to develop our own manufacturing capabilities.

Mr Strive Masiyiwa, African Union Special Envoy, said: "Delivering our first doses to African Union Member States is an unprecedented milestone. We are deploying relentless efforts to help each Member State to reach its goal of immunising 60 per cent of Africans, as recommended by the Africa CDC. Johnson & Johnson AVAT-purchased single-shot vaccines will enable us to considerably improve our vaccination level across the continent."

Dr John Nkengasong, Director of the Africa Centres for Disease Control and Prevention (Africa CDC), said: "During the last months, we have seen the vaccination gap between Africa and other parts of the world widen, and a devastating third wave hit our continent. The deliveries starting now will help us get to the vaccination levels necessary to protect African lives and livelihoods."

The agreement with Johnson & Johnson was made possible through a USD 2 billion facility provided by African Export-Import Bank (Afreximbank), who are also the Financial and Transaction Advisers, Guarantors, Instalment Payment facility providers and Payment Agents...

#### **AVAT to partner with UNICEF in scaling up vaccine deliveries to African Union Member States**

DDIS ABABA/NEW YORK, 2 August 2021 – Having secured access to up to 400 million doses of the J&J COVID-19 vaccine, **the African Union (AU), African Vaccine Acquisition Trust (AVAT) and UNICEF are partnering to ensure the seamless procurement and delivery of vaccines to AU Member States**. This partnership will help ramp up efforts to mitigate the impact of the pandemic as less than 2 per cent of people on the continent are fully vaccinated so far.

"We are building a platform for deeper collaboration that will pave the way to a more robust African response to the pandemic and move the continent towards recovery, leveraging the opportunities to strengthen health systems and support the manufacturing sector for job creation," said Dr. Vera Songwe, United Nations Under-Secretary-General and Executive Secretary of the Economic Commission for Africa...

Established by African leaders, AVAT has spearheaded African efforts on fair equitable access and distribution of vaccines, negotiating vaccine acquisition with pharmaceutical companies to at least 60 per cent of the African population with safe and efficacious vaccines to achieve "herd immunity" by 2022...

:::::  
:::::

#### **Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**Russia: Sputnik V – "the first registered COVID-19 vaccine"**

<https://sputnikvaccine.com/newsroom/pressreleases/>

*Press Releases*

**Argentina and Russia continue to successfully work together to accelerate the vaccination campaign and generate scientific evidence regarding the interchangeability of vaccines**

Press release, 04.08.2021

**Combination of the first component of Sputnik V vaccine (Sputnik Light vaccine) with vaccines by AstraZeneca, Sinopharm and Moderna demonstrates high safety profile during the study in Argentina's Buenos-Aires province**

Press release, 04.08.2021

**SPUTNIK V TEAM STATEMENT ON PRODUCTION SCALE UP IN AUGUST AND SEPTEMBER**

Press release, 04.08.2021

**Laboratorios Richmond to provide Argentina with over 3 million doses of the second component of the Sputnik V vaccine in August with the first 150,000 doses to become available for vaccination this week**

Press release, 03.08.2021

**Test batch of the Sputnik V vaccine produced in Uzbekistan**

Press release, 31.07.2021

**The world's first study of a combination between the AstraZeneca vaccine and the first component of the Sputnik V vaccine (Sputnik Light) in Azerbaijan shows no serious adverse events or COVID infection cases following the vaccination**

Press release, 30.07.2021

::::::

::::::

**India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**Ministry of Health and Family Welfare**

<https://www.mohfw.gov.in/>

COVID-19 INDIA as on :  
07 August 2021, 08:00  
IST (GMT+5:30)

(↑↓ Status change since  
yesterday)

**Active (1.29%)**

**412153 (2006↓)**

**Discharged (97.37%)**

**31055861 (40017↑)**

**Deaths (1.34%)**

**427371 (617↑)**

COVID-19 Vaccination  
as on : 07 August  
2021, 08:00 IST  
(GMT+5:30)

**Total Vaccination : 50,10,09,609 (49,55,138↑)**

**Government of India – Press Information Bureau**

*Latest Press Releases*

**[India's fight against COVID-19 receives a strong impetus as vaccination numbers cross the 50 crore mark: PM](#)** Posted on: 06 Aug 2021

**Indian Council for Medical Research (ICMR)**

<https://www.icmr.gov.in/media.html>

*Press Releases*

*No new digest content identified.*

::::::

::::::

**China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment**

**[China to provide 2 billion COVID-19 vaccines globally this year: Xi](#)**

2021-08-06

BEIJING -- China will strive to provide 2 billion COVID-19 vaccine doses to the world throughout this year and offer 100 million U.S. dollars to COVAX, Chinese President Xi Jinping said on Aug 5 in a written message to the first meeting of the international forum on COVID-19 vaccine cooperation.

The 100 million U.S. dollars to COVAX will mainly go to the distribution of vaccines to developing countries, he said, adding that China would do its best to help developing countries cope with the COVID-19 pandemic.

China is committed to building a global community of health for all and has provided vaccines to the world, especially developing countries. The country actively carried out joint production, which illustrates the concept of vaccines as global public goods, Xi stressed.

"I hope this forum will promote the accessibility and fair distribution of vaccines around the world, strengthen solidarity and cooperation in developing countries, and make new contributions for an early victory against the pandemic," he said...

**[China pledges US\\$ 100 million towards equitable access to COVID-19 vaccines for lower-income countries](#)**

6 August 2021 *Gavi Media Release*

:: The government of the People's Republic of China has pledged US\$ 100 million to the Gavi COVAX Advance Market Commitment (AMC)

:: This latest pledge brings the total raised for the Gavi COVAX AMC to nearly US\$ 10 billion

... "China will continue to do its best to help other lower income countries cope with the COVID-19 pandemic", said President Xi Jinping of China, "and we stand ready to work with international organizations to advance vaccine cooperation to protect communities for a shared future..."

::::::

::::::

::::::

**Emergencies**

**POLIO**

*Public Health Emergency of International Concern (PHEIC)*

**[Polio this week as of 04 August 2021](#)**

:: The United Arab Emirates (UAE) on July 24 announced an additional US\$9.5 million support to the Pakistan Polio Eradication Initiative (PEI). The funding will be used to vaccinate approximately 16 million children during door-to-door immunization campaigns in 84 highest-risk districts as well as an additional US\$376,000 to provide personal protective equipment against COVID-19 for the frontline campaign workers. [Read more...](#)

***Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):***

:: Pakistan: one WPV1 positive environmental sample  
:: Afghanistan: one cVDPV2 case  
:: DR Congo: one cVDPV2 case  
:: Madagascar : seven cVDPV1 positive environmental samples  
:: Nigeria: 16 cVDPV2 cases and six cVDPV2 positive environmental samples  
:: Tajikistan: seven cVDPV2 cases

:::::

:::::

## **WHO/OCHA Emergencies**

***Editor's Note:***

*WHO has apparently reorganized and fundamentally shifted how it judges and tracks "emergencies". We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.*

### **Health emergencies list - WHO**

"The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences."

#### **Crisis in Tigray, Ethiopia**

:: [Ethiopia - Tigray Region Humanitarian Update](#) Situation Report Last updated: 5 Aug 2021

#### **Ebola outbreak, Democratic Republic of the Congo, 2021**

[Last apparent update: 3 May 2021]

#### **Ebola outbreak outbreak, N'Zerekore, Guinea, 2021** [Last apparent update: 3 May 2021]

#### **Coronavirus disease (COVID-19) pandemic** [See COVID above]

#### **Ebola outbreak, Equateur Province, Democratic Republic of the Congo, 2020** [Last apparent update: 19 July 2021]

#### **Ebola outbreak, North Kivu, Ituri, Democratic Republic of the Congo, 2018 – 2020** [Last apparent update: 3 May 2021]

#### **Ebola outbreak, Democratic Republic of the Congo, 2018** [Last apparent update: 24 July 2018]

[Yemen crisis](#) [Last apparent update: 12 February 2021]

[Syria crisis](#) [Last apparent update: 18 June 2021]

[Somalia crisis](#) [Last apparent update: 24 March 2018]

[Nigeria crisis](#) [Last apparent update: 9 May 2018]

[Ebola outbreak, Democratic Republic of the Congo, 2017](#) [Last apparent update: 3 May 2021]

[Zika virus disease outbreak, 2015-2016](#) [Last apparent update: 24 Jan 2020]

[Ebola outbreak: West Africa, 2014-2016](#) [Last apparent update: 3 May 2021]

[Iraq crisis](#) [Last apparent update: 9 Jan 2008]

[South Sudan crisis](#) [Last apparent update: 23 Sep 2020]

[Avian influenza A \(H7N9\) virus outbreak](#) [Last apparent update: 21 May 2021]

[Middle East respiratory syndrome \(MERS-CoV\) outbreak](#) [Last apparent update: 8 July 2019]

[Influenza A \(H1N1\) virus, 2009-2010 pandemic](#) [Last apparent update: 10 Aug 2010]

::::::

### [UN OCHA – Current Emergencies](#)

*Current Corporate Emergencies*

*Northern Ethiopia*

[Ethiopia - Tigray Region Humanitarian Update Situation Report, 05 August 2021](#)

#### *HIGHLIGHTS*

- The UN Under-Secretary-General for Humanitarian Affairs and Emergency Relief Coordinator, Martin Griffiths, made a six-day mission to Ethiopia.
- Over 100,000 children could suffer from severe acute malnutrition in the next 12 months in Tigray – a tenfold increase compared to the average annual caseload.
- Some 175 trucks with humanitarian supplies arrived in Mekelle during the reporting period but this is still not enough, with an estimated 100 trucks needed daily.
- Since mid-May, over one million people were reached with food assistance in Southern, North-Western, Eastern, and South-Eastern Zones.
- Humanitarian partners are scaling up response in neighbouring Afar and Amhara Regions affected by the conflict.

::::::

::::::

**WHO & Regional Offices** [to 7 Aug 2021]

6 August 2021

News release

**Fraudulent "COVID-19 Compensation Lottery Prize" scam, falsely alleges association with WHO and others**

6 August 2021

Departmental news

**COVID-19 vaccines available for all healthcare workers in the Western Pacific Region**

30 July 2021

Departmental news

**Call to Action on Antimicrobial Resistance 2021**

30 July 2021

Statement

**Joint Statement of the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics, and Diagnostics for Developing Countries following its Second Meeting**

30 July 2021

Joint News Release

**New consortium working to boost vaccine production in South Africa**

30 July 2021

Departmental news

**Updated recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19**

30 July 2021

Departmental news

**Health Workforce in COVID-19 Action Series: Time to Protect. Invest. Together.**

28 July 2021

News release

**HE Ellen Johnson Sirleaf and Rt Hon. Helen Clark brief Member States at the United Nations General Assembly on pandemic response**

28 July 2021

Statement

**Elevating political leadership for Pandemic Preparedness and Response Meeting with the UN General Assembly**

The Independent Panel for Pandemic Preparedness and Response

::::::

**WHO Regional Offices**

*Selected Press Releases, Announcements*

**WHO African Region AFRO**

:: On the frontlines in the fight against dangerous misinformation 30 July 2021

Fast-spreading misinformation online is hard to measure, but the 10 organizations and 10 African fact-checking groups that make up the Africa Infodemic Response Alliance are working to track and debunk dangerous myths on the pandemic and COVID-19 vaccines.

:: [COVID-19 widens routine immunization gaps in Africa](#) 29 July 2021

Around 7.7 million African children missed out on vital first doses of Diphtheria-Tetanus-Pertussis, Measles and Polio vaccines in 2020. The nearly 10% rise in missed vaccinations on the previous year in Africa was driven by disruptions to health services by the COVID-19 pandemic, new data by the United Nations Children's Fund (UNICEF) and World Health Organization (WHO) show.

:: [Driving COVID-19 vaccine uptake in Ghana's hard-to-reach communities](#) 29 July 2021

## **WHO Region of the Americas PAHO**

*No new digest content identified*

## **WHO South-East Asia Region SEARO**

:: 6 August 2021 News release

[Over half a billion COVID-19 vaccine doses administered in WHO South-East Asia Region as countries scale up vaccination efforts](#)

## **WHO European Region EURO**

:: [WHO recommends continuing breastfeeding during COVID-19 infection and after vaccination](#) 04-08-2021

:: [COVID-19 cases top 60 million in European Region, says WHO/Europe](#) 02-08-2021

:: [Supporting the implementation of COVID-19 contact tracing in Ukraine](#) 28-07-2021

## **WHO Eastern Mediterranean Region EMRO**

:: [KSrelief partners with WHO in Yemen to save lives from COVID-19](#) 5 August 2021

:: [Identifying challenges and solutions for pandemic influenza preparedness in the Region](#)

2 August 2021

:: [Delta variant sparks current COVID-19 surge in Region amid low vaccination coverage](#)

29 July 2021

## **WHO Western Pacific Region**

:: 6 August 2021 | News release

[COVID-19 vaccines available for all healthcare workers in the Western Pacific Region](#)

::::::

## **New WHO Publications [Selected]**

<https://www.who.int/publications/i>

3 August 2021

### **Global Patient Safety Action Plan 2021-2030**

...The purpose of the action plan is to provide strategic direction for all stakeholders for eliminating avoidable harm in health care and improving patient safety in different practice domains through policy actions on safety and quality of health services, as well as for implementation of recommendations at the point of care. The action plan provides a framework for countries to develop their respective national action plans on patient safety, as well to align existing strategic instruments for improving patient safety in all clinical and health-related programmes.

PDF: <https://apps.who.int/iris/rest/bitstreams/1360307/retrieve>

3 August 2021

**2020 Annual Meeting Report- International Coordinating Group (ICG) on Vaccine Provision for Cholera, Meningitis, and Yellow Fever**

30 July 2021

**Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19**

*Interim guidance 30 July 2021*

*Overview*

These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.

PDF: <https://apps.who.int/iris/rest/bitstreams/1359655/retrieve>

:::::

:::::

**CDC/ACIP [U.S.]** [to 7 Aug 2021]

<http://www.cdc.gov/media/index.html>

<https://www.cdc.gov/vaccines/acip/index.html>

*Latest News Releases, Announcements*

**New CDC-Funded Pilot Program in Georgia Uses Public Art to Increase Confidence in COVID-19 Vaccination** Friday, August 6, 2021

**New CDC Study: Vaccination Offers Higher Protection than Previous COVID-19 Infection**

Friday, August 6, 2021

**CDC Issues Eviction Moratorium Order in Areas of Substantial and High Transmission**

Tuesday, August 3, 2021

**CDC Extends Order at the Southern and Northern Land Borders** Monday, August 2, 2021

**Statement from CDC Director Rochelle P. Walensky, MD, MPH on Today's MMWR** Friday, July 30, 2021

**CDC awards \$117 Million to Advance Innovation and Health Equity in Federal Initiative to End HIV** Tuesday, July 27, 2021

:::::

**MMWR News Synopsis Friday, August 6, 2021**

:: [COVID-19 Vaccine Safety in Adolescents Aged 12–17 Years — United States, December 14, 2020–July 16, 2021 \(Early Release July 30, 2021\)](#)

:: [Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021 \(Early Release July 30, 2021\)](#)

## **MMWR News Synopsis Friday, July 30, 2021**

- :: [Progress Toward Hepatitis B Control — World Health Organization European Region, 2016–2019](#)
- :: [Disparities in COVID-19 Vaccination Coverage Among Health Care Personnel Working in Long-Term Care Facilities, by Job Category — National Healthcare Safety Network, United States, March 2021](#)
- :: [SARS-CoV-2 Infection in Public School District Employees Following a District-Wide Vaccination Program — Philadelphia County, Pennsylvania, March 21–April 23, 2021 \(Early Release July 23, 2021\)](#)
- :: [Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage \(Early Release July 27, 2021\)](#)

::::::

## **Coronavirus Disease 2019 (COVID-19)- CDC**

*Approximately 50 announcements/reports/data summaries.*

::::::

::::::

**Africa CDC** [to 7 Aug 2021]

<http://www.africacdc.org/>

*News*

### **Africa announces the rollout of 400m vaccine doses to the African Union Member States and the Caribbean**

5 August 2021

::::::

::::::

**China CDC** <http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 7 Aug 2021]

<http://en.nhc.gov.cn/>

*News*

### **Aug 7: Daily briefing on novel coronavirus cases in China**

On Aug 6, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 107 new cases of confirmed infections.

### **China to provide 2 billion COVID-19 vaccines globally this year: Xi**

2021-08-06

### **China says latest COVID-19 resurgence more complicated but 'controllable'**

2021-08-06

BEIJING — The latest resurgence of COVID-19 in China, caused mainly by the Delta variant, is more complicated but the epidemic is generally controllable, Chinese officials said on Aug 5.

In the latest wave, 15 provincial-level regions — out of 31 — on the Chinese mainland have reported COVID-19 infections, said He Qinghua, a senior official with the National Health Commission (NHC), at a press conference organized by the State Council inter-agency task force.

*"CONTROLLABLE"*

"As long as local authorities strictly implement various prevention and control measures, I think the epidemic will be largely under control within two to three incubation periods," he said...

### **China imposes massive travel restrictions to combat Delta outbreak**

2021-08-04

- China has imposed massive travel restrictions to contain the spread of the Delta variant.
- All 31 provincial-level regions in the Chinese mainland have urged citizens not to go to medium and high-risk areas for COVID-19 or leave the provinces where they live unless it is necessary.
- Twenty-three railway stations have halted ticket sales for Beijing-bound passengers departing from these stations.

### **National Medical Products Administration – PRC [to 7 Aug 2021]**

<http://english.nmpa.gov.cn/news.html>

*News*

### **Over 1.72b doses of COVID-19 vaccines administered in China**

2021-08-06

More than 1.72 billion doses of COVID-19 vaccines had been administered in China by Wednesday, the National Health Commission said on Aug 5.

### **CCDC Weekly - Weekly Reports: Current Volume (3)**

2021-08-06 / No. 32

[PDF of this issue](#)

[Preplanned Studies: Changes in Public Perception and Behaviors under Compound Heatwave in COVID-19 Epidemic — Beijing, China, 2020](#)

[Outbreak Reports: A COVID-19 Outbreak Emerging in a Food Processing Company — Harbin City, Heilongjiang Province, China, January–February 2021](#)

[Notes from Field: An Immunocompetent Patient with High Neutralizing Antibody Titers Who Shed COVID-19 Virus for 169 days — China, 2020](#)

:::::  
:::::

### **Organization Announcements**

*Editor's Note:*

Careful readers will note that the number and range of organizations now monitored in our *Announcements* section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

### **Paul G. Allen Frontiers Group [to 7 Aug 2021]**

<https://alleninstitute.org/what-we-do/frontiers-group/news-press/>

*News*

*No new digest content identified.*

### **BARDA – U.S. Department of HHS [to 7 Aug 2021]**

<https://www.phe.gov/about/barda/Pages/default.aspx>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 7 Aug 2021]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 7 Aug 2021]

<https://www.gatesmri.org/>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*No new digest content identified.*

**CARB-X** [to 7 Aug 2021]

<https://carb-x.org/>

*News*

07.29.2021 |

**[CARB-X celebrates five years of progress in early-stage product development against antibiotic-resistant bacteria](#)**

CARB-X, a global non-profit partnership led by Boston University, is celebrating five years of progress in funding and supporting the development of innovative products targeting antibiotic-resistant bacteria. Since it was founded in July 2016, CARB-X has invested \$361 million in non-dilutive funding to develop innovative therapeutics including new classes of antibiotics and non-traditional agents, vaccines and other preventatives such as CRISPR-phage, microbiome-modifying agents and antibodies, and rapid diagnostics.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 7 Aug 2021]

<https://centerforvaccineethicsandpolicy.net/>

*News/Analysis/Statements*

:: Past weekly editions and posting of all segments of ***Vaccines and Global Health: The Week in Review*** are [available here](#).

:: [NEW] ***Informed Consent: A Monthly Review – August 2021*** is now posted [here](#)

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 7 Aug 2021]

<http://cepi.net/>

*Latest News*

**[Efforts to advance Rift Valley fever vaccines progress with new CEPI partnership](#)**

Serum material donated from patients recovered from Rift Valley fever will support the development of a reference tool used to assess Rift Valley fever vaccines undergoing clinical trials.

End Pandemics  
06 Aug 2021

**CEPI and Universiti Malaya announce new collaboration to advance Nipah virus research**

The research aims to characterize and better understand immune responses generated against the virus - one of the deadliest pathogens known to infect humans.

End Pandemics  
29 Jul 2021

**Largest ever Lassa fever study expands to more countries in West Africa**

Up to 23,000 participants will be enrolled into the research programme in Benin, Guinea, Liberia, and Sierra Leone, as well as Nigeria, which began collecting data in December 2020.

End Pandemics  
28 Jul 2021

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 7 Aug 2021]

<https://cioms.ch/>  
*News; Publications*  
*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency** [to 7 Aug 2021]

<https://www.darpa.mil/news>  
*News*  
8/6/2021

**DARPA Selects Teams to Develop Novel Therapeutics for Combating Multi-Drug Resistant Microbial Infections**

DARPA today announced that it has selected three performer teams to support the Harnessing Enzymatic Activity for Lifesaving Remedies (HEALR) program. Groups from Yale University, University of Washington, and Broad Institute plan to utilize a new therapeutic approach and novel protein degradation strategies/modalities to permit a flexible and rapid response for targeting emerging microbial threats.

**Duke Global Health Innovation Center** [to 7 Aug 2021]

<https://dukeghic.org/>  
*Our Blog*  
*No new digest content identified.*

**EDCTP** [to 7 Aug 2021]

<http://www.edctp.org/>  
*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*No new digest content identified.*

**Emory Vaccine Center** [to 7 Aug 2021]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

**[COVID-19 survivors may possess wide-ranging resistance to the disease](#)**

Woodruff Health Sciences Center | July 22, 2021

**European Vaccine Initiative** [to 7 Aug 2021]

<http://www.euvaccine.eu/>

*Latest News*

**[EVI to lead Inno4vac, a new European public-private partnership to innovate vaccine development](#)**

*The Innovative Medicines Initiative 2 (IMI2) Joint Undertaking mobilised more than € 33 million to support Inno4vac, an innovative public-private partnership to accelerate vaccine R&D timelines. It will focus on the design and application of new and highly advanced predictive models to allow a faster development and manufacturing of novel vaccines.*

July 29th, 2021

**FDA** [to 7 Aug 2021]

<https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/default.htm>

*Press Announcements*

**[August 6, 2021 - Coronavirus \(COVID-19\) Update: August 6, 2021](#)**

**[August 3, 2021 - Coronavirus \(COVID-19\) Update: August 3, 2021](#)**

:: In mid-July, the FDA held a stakeholder call to discuss COVID-19 vaccines, including preliminary reports of Guillain-Barré Syndrome following Janssen (Johnson & Johnson) COVID-19 vaccination. Acting FDA Commissioner Janet Woodcock, M.D. and the Director of FDA's Center for Biologics Evaluation and Research, Peter Marks, M.D., Ph.D. were featured speakers. The call can be found on the [FDA's YouTube page](#)<sup>External Link Disclaimer</sup>.

**[July 30, 2021 - Coronavirus \(COVID-19\) Update: July 30, 2021](#)**

:: Today, the FDA revised the [Emergency Use Authorization](#) (EUA) for REGEN-COV (casirivimab and imdevimab, administered together) to add an authorization of REGEN-COV for emergency use as post-exposure prophylaxis (prevention) for COVID-19 in adults and pediatric individuals (12 years of age and older weighing at least 40 kilograms) who are at high risk for progression to severe COVID-19, including hospitalization or death.

:: On Wednesday, the FDA authorized an extension for the shelf life of the refrigerated Janssen (Johnson & Johnson) COVID-19 Vaccine, allowing the product to be stored at 2-8 degrees Celsius for six months. This extension from four and a half months to six months was granted following a thorough review of data submitted by Janssen and applies to all refrigerated vials of Janssen COVID-19 Vaccine that have been held in accordance with the manufacturer's storage conditions. The concurrence letter can be read [here](#).

**Fondation Mérieux** [to 7 Aug 2021]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 7 Aug 2021]

<https://www.gavi.org/>

*News Releases*

6 August 2021

**[China pledges US\\$ 100 million towards equitable access to COVID-19 vaccines for lower-income countries](#)**

*[See COVID above for detail]*

5 August 2021

**[First doses donated by Spain through COVAX arrive to Peru, Guatemala, Paraguay and Nicaragua](#)**

4 August 2021

**[New financing agreement boost for malaria vaccine](#)**

30 July 2021

**[First Swedish doses delivered through COVAX](#)**

30 July 2021

**[First deliveries of Norway-donated COVID-19 vaccines to COVAX](#)**

26 July 2021

**[COVAX and World Bank to Accelerate Vaccine Access for Developing Countries](#)**

**GHIT Fund** [to 7 Aug 2021]

<https://www.ghitfund.org/newsroom/press>

*GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that*

*No new digest content identified.*

**Global Fund** [to 7 Aug 2021]

<https://www.theglobalfund.org/en/news/>

*News & Stories*

*No new digest content identified.*

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 7 Aug 2021]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 7 Aug 2021]  
<http://www.hillemanlabs.org/>  
*Website reports "under maintenance" at inquiry*

**Human Vaccines Project** [to 7 Aug 2021]  
<http://www.humanvaccinesproject.org/>  
*News*  
*News webpage not responding at inquiry*

**IAVI** [to 7 Aug 2021]  
<https://www.iavi.org/newsroom>  
*Latest News*  
*FEATURES*  
August 3, 2021  
**[Europe-Africa research partnership launches HIV vaccine clinical trial in three African countries](#)**

*Vaccine candidate targets vulnerabilities common across many HIV-1 variants.*

The first volunteers have been vaccinated in Lusaka, Zambia, in a Phase I HIV vaccine trial led by a consortium of researchers in Africa and Europe. The trial, known as [HIV-CORE 006](#), will evaluate the safety, tolerability, and immunogenicity of an HIV vaccine candidate known as HIVconsvX. This novel vaccine construct comprises three immunogens that target vulnerable regions common across most HIV variants. Studies using an earlier version of HIVconsvX showed that the most vulnerable parts of HIV neglected by the immune system during natural infection can induce robust immune responses<sup>1</sup>.

HIV-CORE 006 builds on extensive research expertise, infrastructure, and community engagement programs within IAVI's network of Africa [clinical research center](#) (CRC) partners. The following CRCs are GREAT consortium members and will participate in HIV-CORE 006:

- Uganda: [MRC/UVRI and LSHTM Uganda Research Unit](#)
- Kenya: [KAVI-Institute of Clinical Research; KEMRI-Wellcome Trust Research Programme](#)
- Zambia: [Center for Family Health Research Zambia](#)

The trial is sponsored by the [Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership \(GREAT\)2](#) consortium and is supported by the European and Developing Countries Clinical Trials Partnership (EDCTP), with co-funding from IAVI and Oxford University...

**International Coalition of Medicines Regulatory Authorities [ICMRA]**  
<http://www.icmra.info/drupal/en/news>  
*Selected Statements, Press Releases, Research*  
**[Supply Chain Integrity](#)**  
*Recommendations on common technical denominators for track and trace systems to allow for interoperability*  
August 6, 2021

The International Coalition of Medicines Regulatory Authorities (ICMRA) published recommendations to facilitate the use of track and trace systems at global level. The [paper](#) identifies common technical

denominators that allow different systems to exchange and use the available information on medicines and their supply chains in order to protect public health.

In this paper, international regulators emphasise that the interoperability of track and trace systems helps to protect public health by improving information sharing in case of quality defects, reducing shortages, contributing to the fight against falsified medicines and supporting pharmacovigilance activities. A common understanding of these potential benefits of interoperability is fundamental to promoting global planning and implementation of interoperable systems for medicines.

The ICMRA paper was open for public consultation from November 2020 to February 2021. The extensive and helpful feedback was carefully analysed and reviewed in order to refine and finalise the recommendations on common technical denominators for track and trace systems. More details on the comments received and the ICMRA analysis of these comments is available in a separate [document](#).

[Recommendations on common technical denominators for track and trace systems to allow for interoperability](#)

[Overview of responses to public consultation on track and trace recommendations](#)

**ICRC** [to 7 Aug 2021]

<https://www.icrc.org/en/whats-new>

*Selected News Releases, Statements, Reports*

**[Health Situation in Yemen](#)**

Most of the population lack access to health care due to the destruction of the health facilities in their areas or due to lack of financial resources.

05-08-2021 | Article

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

*No new digest content identified.*

**IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

*No new digest content identified.*

**IFRC** [to 7 Aug 2021]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Selected Press Releases, Announcements*

*Armenia, Azerbaijan, Europe, Georgia, Kazakhstan, Montenegro, Russia, Turkey, Ukraine*

**[IFRC: Delta variant a huge threat in Eastern Europe, South Caucasus and Central Asia](#)**

Budapest/Geneva, 6 August 2021 – The International Federation of Red Cross and Red Crescent Societies (IFRC) is calling for more assistance and for vaccinations to be stepped up in Eastern Europe, South Caucasus and Central Asia, where rising COVID-19 ...

6 August 2021

*Algeria, Libya, Middle East and North Africa, Morocco, Tunisia*

**IFRC: Inclusive vaccination and protection measures urgently needed to stop the new pandemic waves in North Africa**

Beirut, 02 August 2021 – The International Federation of Red Cross and Red Crescent Societies (IFRC) in the Middle East and North Africa, is concerned that the increasing COVID-19 transmissions in the region could spark a domino effect with catastrophi ...

2 August 2021

**Institut Pasteur** [to 7 Aug 2021]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*No new digest content identified.*

**IOM / International Organization for Migration** [to 7 Aug 2021]

<http://www.iom.int/press-room/press-releases>

*News*

*No new digest content identified.*

**IVAC** [to 7 Aug 2021]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

**IVI** [to 7 Aug 2021]

<http://www.ivi.int/>

*Selected IVI News, Announcements, Events*

**THECA consortium begins Vi-TT typhoid conjugate vaccine phase IV effectiveness study in Ghana**

July 26, 2021

**JEE Alliance** [to 7 Aug 2021]

<https://www.jeealliance.org/>

*Selected News and Events*

*No new digest content identified.*

**Johns Hopkins Center for Health Security** [to 7 Aug 2021]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News*

**New Addendum 2021 Report: COVID-19 Planning Guide and Self-Assessment Toolkit for Higher Education**

July 30, 2021

**MSF/ Médecins Sans Frontières** [to 7 Aug 2021]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Central American Migration*

**[COVID-19 forces thousands of migrants to cross perilous jungle from Colombia to Panama in search of saf...](#)**

Project Update 5 Aug 2021

**[Public health partnership launched to tackle silent epidemic of hepatitis C](#)**

Press Release 27 Jul 2021

**National Academy of Medicine** - USA [to 7 Aug 2021]

<https://nam.edu/programs/>

*Selected News/Programs*

**[Expert Papers from the NAM Identify Lessons Learned and Compelling Needs for Quality, Safety, and Standards Organizations and Biomedical Research after COVID-19](#)**

July 26, 2021

In response to the devastating impact of COVID-19 on the American health system, the National Academy of Medicine (NAM) has convened experts in 9 sectors of health, health care, and biomedical research to review how each sector responded to COVID-19, identify challenges encountered in combating the pandemic, and outline what opportunities exist to reinforce, revitalize, and transform the health system. These insights are being released as 9 *NAM Perspectives* discussion papers between April and August of 2021, and then bundled into a NAM Special Publication titled *Emerging Stronger After COVID-19: Priorities for Health System Transformation*, scheduled to be released in Fall 2021...  
[See COVID above for example]

**National Academy of Sciences** - USA [to 7 Aug 2021]

<http://www.nasonline.org/news-and-multimedia/>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 7 Aug 2021]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 7 Aug 2021]

<http://www.nih.gov/news-events/news-releases>

*News Releases*

*No new digest content identified.*

**PATH** [to 7 Aug 2021]

<https://www.path.org/media-center/>

*Press Releases*

**PATH welcomes landmark financing agreement for GSK's malaria vaccine**

Seattle, WA, August 4, 2021 — PATH congratulates Gavi, the Vaccine Alliance, GSK, and MedAccess for joining forces to help ensure an ongoing supply of the first malaria vaccine, GSK's RTS,S/AS01E. This is another important step toward ensuring access to the vaccine for every child that could benefit from it.

PATH has collaborated in the development of the RTS,S/AS01E malaria vaccine since 2001, first with GSK to advance the vaccine through Phase 2 and Phase 3 trials in Africa, and, since 2017, with GSK and the World Health Organization (WHO) to support pilot implementation of the vaccine in areas of Ghana, Kenya, and Malawi. At the same time, PATH continues efforts to accelerate development of next-generation vaccines and biologics, working with a wide range of academic, business, and governmental organizations.

"It is very encouraging to see leaders in the global health community step up to help ensure access to the RTS,S vaccine," says Carla Botting, Director of Malaria Market Access and Strategy at PATH. "GSK took a bold step when they agreed to donate millions of doses of vaccine for use in the Malaria Vaccine Implementation Program (MVIP). That donation is helping to make it possible to generate data for a potential WHO recommendation for wider use of the vaccine. Now, Gavi and MedAccess are helping to share the risk so that GSK can continue manufacturing the RTS,S antigen, which will help enable early access to the vaccine and the ability to vaccinate millions more children."...

**Sabin Vaccine Institute** [to 7 Aug 2021]

<http://www.sabin.org/updates/pressreleases>

*Statements and Press Releases*

*No new digest content identified.*

**UNAIDS** [to 7 Aug 2021]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

**UNAIDS report shows that people living with HIV face a double jeopardy, HIV and COVID-19, while key populations and children continue to be left behind in access to HIV services**

*People living with HIV are at a higher risk of severe COVID-19 illness and death, yet the vast majority are denied access to COVID-19 vaccines. Key populations and their sexual partners account for 65% of new HIV infections but are largely left out of both HIV and COVID-19 responses—800 000 children living with HIV are not on the treatment they need to keep them alive*

GENEVA, 14 July 2021—The [UNAIDS Global AIDS Update 2021](#), launched today, highlights evidence that people living with HIV are more vulnerable to COVID-19, but that widening inequalities are preventing them from accessing COVID-19 vaccines and HIV services.

Studies from England and South Africa have found that the risk of dying from COVID-19 among people living with HIV was double that of the general population. In sub-Saharan Africa, which is home to two thirds (67%) of people living with HIV, less than 3% had received at least one dose of a COVID-19 vaccine by July 2021. At the same time, HIV prevention and treatment services are eluding key populations, as well as children and adolescents.

COVID-19 vaccines could save millions of lives in the developing world but are being kept out of reach as rich countries and corporations hold on tightly to the monopoly of production and delivery of supplies for profit. This is having a severe impact around the world as health systems in developing countries become overwhelmed, such as in Uganda, where football stadiums are being turned into makeshift hospitals.

"Rich countries in Europe are preparing to enjoy the summer as their populations have easy access to COVID-19 vaccines, while the global South is in crisis," said Winnie Byanyima, Executive Director of UNAIDS. "We have failed to learn the lessons of HIV, when millions were denied life-saving medicines and died because of inequalities in access. This is totally unacceptable."

The new UNAIDS report shows how COVID-19 lockdowns and other restrictions have badly disrupted HIV testing—in many countries this has led to steep drops in HIV diagnoses, referrals to care services and HIV treatment initiations. In KwaZulu-Natal, South Africa, for example, there was a 48% drop in HIV testing after the first national lockdown was imposed in April 2020. There were also fewer new HIV diagnoses and a marked drop in treatment initiation. This occurred as 28 000 HIV community health-care workers were shifted from HIV testing to COVID-19 symptom screening.

The report, *Confronting inequalities*, shows that in 2020 the 1.5 million new HIV infections were predominantly among key populations and their sexual partners. People who inject drugs, transgender women, sex workers and gay men and other men who have sex with men, and the sexual partners of these key populations, accounted for 65% of HIV infections globally in 2020. Key populations accounted for 93% of new HIV infections outside of sub-Saharan Africa, and 35% within sub-Saharan Africa. However, they remain marginalized and largely out of reach of HIV services in most countries...

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 7 Aug 2021]

<http://www.unhcr.org/en-us/media-centre.html>

*Selected News Releases, Announcements*

**[UNHCR welcomes U.S. continued efforts to implement measures that protect refugees and asylum-seekers](#)**

29 Jul 2021

**[The 1951 Refugee Convention: 70 years of life-saving protection](#)**

28 Jul 2021

**[UNHCR urges states to protect refugees' rights, not to instrumentalize their plight](#)**

27 Jul 2021

**UNICEF** [to 7 Aug 2021]

<https://www.unicef.org/media/press-releases>

*Press Releases, News Notes, Statements [Selected]*

*Press release*

08/02/2021

**[AVAT to partner with UNICEF in scaling up vaccine deliveries to African Union Member States](#)**

*News note*

07/27/2021

**Geneva Palais briefing note on the current COVID-19-induced education crisis**

This is a summary of what was said by UNICEF Spokesperson James Elder – to whom quoted text may be attributed - at today's press briefing at the Palais des Nations in Geneva

*Press release*

07/26/2021

**UNICEF signs supply agreement for Sinovac COVID-19 vaccine**

**Unitaid** [to 7 Aug 2021]

<https://unitaid.org/>

*Featured News*

04 August 2021

**Research begins into new digital tools to support patients and healthcare workers through tuberculosis treatment**

27 July 2021

**Unitaid paving the way for hepatitis C elimination**

26 July 2021

**Innovative agreement launches affordable, optimal second-line HIV treatment in low- and middle-income countries**

**Vaccine Equity Initiative** [to 7 Aug 2021]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 7 Aug 2021]

<https://www.vaccineacceptance.org/>

*Announcements*

*No new digest content identified.*

**Vaccine Confidence Project** [to 7 Aug 2021]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

**Coronavirus global impact**

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

**Vaccine Education Center – Children's Hospital of Philadelphia** [to 7 Aug 2021]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

## **Vaccine Update for Providers**

July 2021

*New animation! How mRNA vaccines work*

**Wellcome Trust** [to 7 Aug 2021]

<https://wellcome.ac.uk/news>

*News and reports*

*Q&A*

Charlie Weller

### **Why do we need a new generation of Covid-19 vaccines?**

4 August 2021

The first Covid-19 vaccines have been very effective, but there's plenty of room for improvement, especially for dealing with new variants. Charlie Weller talks about the potential benefits of new generations of Covid-19 vaccines.

*Explainer*

### **How can the world adapt to Covid-19 in the long term?**

28 July 2021

As the acute phase of the pandemic passes, Covid-19 will remain with us as an endemic disease – still around, but a manageable threat. What does this mean, and what must we do to stop it from erupting again?

**The Wistar Institute** [to 7 Aug 2021]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*

**WFPHA: World Federation of Public Health Associations** [to 7 Aug 2021]

<https://www.wfpha.org/>

*Latest News*

*No new digest content identified.*

**World Bank** [to 7 Aug 2021]

<http://www.worldbank.org/en/news/all>

*Selected News, Announcements*

### **Africa announces the rollout of 400m vaccine doses to the African Union Member States and the Caribbean**

ADDIS ABABA, 5 August, 2021 – His Excellency President Cyril Ramaphosa, President of the Republic of South Africa and African Union (AU) COVID-19 Champion, is pleased to announce the start of monthly...

Date: August 05, 2021 Type: Press Release

*[See COVID above for detail]*

### **Gulf Economic Update: COVID-19 Pandemic and the Road to Diversification**

In this issue of the Gulf Economic Update, the focus is on fiscal revenues and structural reforms including strategic investments in digitalization and telecommunications. Strategic investment in advanced...

Date: August 04, 2021 Type: Publication

### **World Bank Support to Bangladesh to Address Challenges Created by Influx of Displaced Rohingya Population (FAQs)**

1. What is the World Bank's position on the repatriation of the displaced Rohingya population? The World Bank is helping Bangladesh address the needs of the displaced Rohingya population until their...

Date: August 03, 2021 Type: Statement

### **World Bank Group Mobilizes Over \$29 billion to Support Latin America and the Caribbean Region Respond to Pandemic**

WASHINGTON, August 3, 2021—In response to COVID-19 severely damaging the lives and livelihoods of millions of people in Latin America and the Caribbean countries, the World Bank Group deployed a record...

Date: August 02, 2021 Type: Press Release

### **Joint Statement of the Multilateral Leaders Task Force on COVID-19 Vaccines, Therapeutics, and Diagnostics for Developing Countries following its Second Meeting**

New Global Database to Enhance Transparency and Improve Delivery of COVID-19 Tools

WASHINGTON, July 30, 2021 — The Task Force on COVID-19 Vaccines, Therapeutics and Diagnostics for Developing Countries...

Date: July 30, 2021 Type: Statement

*[See COVID above for detail]*

### **COVAX and World Bank to Accelerate Vaccine Access for Developing Countries**

New mechanism builds on Gavi COVAX Advance Market Commitment (AMC) cost-sharing arrangement

WASHINGTON, July 26, 2021 – COVAX and the World Bank will accelerate COVID-19 vaccine supply for developing...

Date: July 26, 2021 Type: Press Release

### **World Customs Organization – WCO [to 7 Aug 2021]**

<http://www.wcoomd.org/>

*Latest News – Selected Items*

02 August 2021

### **WCO Secretary General addresses G20 Culture Ministers' Meeting in Rome**

### **World Organisation for Animal Health (OIE) [to 7 Aug 2021]**

<https://www.oie.int/en/for-the-media/press-releases/2021/>

*Press Releases, Statements*

*Press Release*

### **Urgent action needed to curb the spread of African swine fever in the Americas**

30 July 2021

*News*

**Global report indicates decreasing trend in antimicrobials intended for use in the animal sector**

27 July 2021

**WTO - World Trade Organisation** [to 7 Aug 2021]

[http://www.wto.org/english/news\\_e/news\\_e.htm](http://www.wto.org/english/news_e/news_e.htm)

*WTO News and Events*

**STDF Annual Report highlights efforts to boost SPS capacity despite pandemic challenges**

2 August 2021

The latest annual report from the Standards and Trade Development Facility (STDF), launched on 2 August, highlights the continued efforts by developing and least developed countries to strengthening their food safety, animal and plant health capacity despite the challenges posed by the COVID-19 pandemic.

**IMF, World Bank, WHO, WTO launch joint vaccine information website**

30 July 2021

The heads of the International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization launched a new website on 30 July which will serve as a platform for information on access to COVID-19 vaccines, therapeutics and diagnostics and on the activities of the organizations in tackling the pandemic.

**WTO report: Full trade recovery at risk without equitable vaccine roll-out**

29 July 2021

WTO economies from mid-October 2020 to mid-May 2021 exercised trade policy restraint and refrained from an acceleration of protectionism that would have further harmed a world economy reeling from the COVID-19 pandemic, according to the Director-General's mid-year report on trade-related developments presented to members on 29 July. The report calls on WTO members to ensure that markets remain open and predictable, and warns that failing to ensure wider access to COVID-19 vaccines could undermine the global economic and trade recovery.

::::::

**ARM [Alliance for Regenerative Medicine]** [to 7 Aug 2021]

[Press Releases - Alliance for Regenerative Medicine \(alliancerm.org\)](#)

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 7 Aug 2021]

<https://www.bio.org/press-releases>

*Press Releases, Letters, Testimony, Comments [Selected]*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 7 Aug 2021]

<http://www.dcvmn.org/>

*News; Upcoming events*  
*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 7 Aug 2021]

<https://internationalbiotech.org/news/>

*News*

**[ICBA Statement on WHO Recommendations on Human Genome Editing](#)**

Jul. 28 2021

**IFPMA** [to 7 Aug 2021]

<http://www.ifpma.org/resources/news-releases/>

*Selected Press Releases, Statements, Publications*

**[R&D-based pharmaceutical industry's innovative partnerships to meet urgent global supply needs](#)**

21 July 2021

IFPMA member companies are at the forefront of the global effort to develop a safe and effective COVID-19 vaccine and scale up manufacturing to ensure equitable access to people around the world. In less than a year, several vaccines candidates have been approved or are in advanced Phase III clinical trials with encouraging results. An impressive and unprecedented manufacturing scale-up is also taking place. Most collaborations - if not all - involved some sort of licensing and transfer of technology, which would not be possible in the absence of a robust global IP system.

**International Alliance of Patients' Organizations – IAPO** [to 7 Aug 2021]

<https://www.iapo.org.uk/news/topic/6>

*Press and media [Selected]*

*No new digest content identified.*

**PhRMA** [to 7 Aug 2021]

<http://www.phrma.org/>

*Latest News [Selected]*

**[Ensuring global vaccine equity requires eliminating trade and regulatory barriers](#)**

August 5, 2021

Trade barriers hamper the COVID-19 vaccine manufacturing process and have direct consequences for global vaccine production and supply...

For example, tariffs and export restrictions on finished vaccines slow the global response to COVID-19 by limiting the ability of people in countries throughout the world to acquire life-saving vaccines. Tariffs and export restrictions on raw materials needed for the vaccine production also slow the global response to COVID-19 by disrupting vaccine manufacturing processes and undermining efforts to promote equitable global vaccine distribution.

The vaccine manufacturing process relies on a complex global network of suppliers that source the raw materials and equipment needed for vaccine production. **One COVID-19 vaccine, for example, requires 280 components, relies on 86 suppliers in 19 different countries and utilizes three different manufacturing plants for production.** Other industries also depend on many of these same raw materials and equipment, which means that vaccine manufacturers must compete for these

essential supplies. The imposition of a tariff or export restriction on any one of these components impedes global vaccine production and distribution.

In addition to being dependent on a vast network of raw materials and equipment suppliers, the vaccine production process depends heavily on highly skilled technical workers, trained to execute specialized and critical functions across the vaccine manufacturing lifecycle. **Currently, vaccines are being produced in approximately 70 countries, all of which are home to collaborative efforts to close the vaccine gap.** A highly skilled workforce is required on the ground wherever vaccine production occurs, and governments should prioritize the movement of these necessary workers for COVID-19 vaccine manufacturing.

These and other trade and regulatory barriers hamper the manufacturing process and have direct consequences for global vaccine production and supply. ..

*Blog Pos*

### **Setting the record straight: Addressing common misconceptions about the COVID-19 vaccine**

August 4, 2021

We all must do our part to keep our communities safe, and getting vaccinated is the best protection against COVID-19.

*Blog Post*

### **Increasing global access to vaccines by optimizing production**

July 29, 2021

Companies have established an unprecedented number of new manufacturing partnerships, creating a global network to produce vaccines at unprecedented speed.

*Blog Post*

\* \* \* \*

### ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

### **AJOB Empirical Bioethics**

Volume 12, 2020 Issue 3

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 23, Number 8: E597-665 Aug 2021

<https://journalofethics.ama-assn.org/issue/economic-decision-modeling-health-care>

***Economic Decision Modeling in Health Care***

Rising health care costs in the United States have created the need to identify prevention and treatment strategies that are both effective and economical. Decision modeling studies aim to help policy makers, organizational leaders, and clinicians quantify and compare prospective costs and benefits of interventions in standardized ways. But health care system operations, patients' behaviors, and clinicians' behaviors are extremely complex and hard to accurately predict. Good analysis of what models yield requires identifying which assumptions should shape clinical practice decisions and patients' health care experiences.

[Reviewed earlier]

**American Journal of Infection Control**

August 2021 Volume 49 Issue 8p973-1092

<http://www.ajicjournal.org/current>

*Major Articles*

**Lived experiences of frontline workers and leaders during COVID-19 outbreaks in long-term care: A qualitative study**

Brandon Yau, Rohit Vijn, Jessica Prairie, Geoff McKee, Michael Schwandt

Published online: March 21, 2021

**The role of mask mandates, stay at home orders and school closure in curbing the COVID-19 pandemic prior to vaccination**

Bhuma Krishnamachari, Alexander Morris, Diane Zastrow, Andrew Dsida, Brian Harper, Anthony J. Santella

Published online: February 09, 2021

p1036-1042

**American Journal of Preventive Medicine**

August 2021 Volume 61 Issue 2 p149-310

<https://www.ajpmonline.org/current>

*Research Letters*

**Demographic Benchmarks for Equitable Coverage of COVID-19 Vaccination**

Kushagra Vashist, Tabia Akintobi, Robert A. Bednarczyk, K.M. Venkat Narayan, Shivani A. Patel

Published online: April 28, 2021

p291-293

**American Journal of Public Health**

July 2021 111(52)

<http://ajph.aphapublications.org/toc/ajph/current>

***Supplement 2 2021***

***When Dying Really Counts***

This new fully Open Access supplement issue looks at the urgent need to improve the quality of mortality data and routine surveillance in the context of COVID-19 and beyond. Consequences of

inaccuracies in mortality data threaten the mission of public health, while challenges facing the professions of those who encounter and study death are facing unprecedented pressures

**American Journal of Tropical Medicine and Hygiene**

Volume 104 (2021): Issue 4 (Apr 2021)

<https://www.ajtmh.org/view/journals/tpmd/104/4/tpmd.104.issue-4.xml>

[Reviewed earlier]

**Annals of Internal Medicine**

July 2021 Volume 174, Issue 7

[Reviewed earlier]

**Artificial Intelligence – An International Journal**

Volume 297 August 2021

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/297/suppl/C>

[New issue; No digest content identified]

**BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 7 Aug 2021)

[No new digest content identified]

**BMJ Global Health**

August 2021 - Volume 6 - Suppl 5

[https://gh.bmjjournals.org/content/6/Suppl\\_5](https://gh.bmjjournals.org/content/6/Suppl_5)

**Digital Innovations for Community and Primary Health in India**

*Analysis*

**[Rebooting consent in the digital age: a governance framework for health data exchange](#)**

(22 July, 2021)

Nivedita Saksena, Rahul Matthan, Anant Bhan, Satchit Balsari

*Abstract*

In August 2020, India announced its vision for the National Digital Health Mission (NDHM), a federated national digital health exchange where digitised data generated by healthcare providers will be exported via application programme interfaces to the patient's electronic personal health record. The NDHM architecture is initially expected to be a claims platform for the national health insurance programme 'Ayushman Bharat' that serves 500 million people. Such large-scale digitisation and mobility of health data will have significant ramifications on care delivery, population health planning, as well as on the rights and privacy of individuals. Traditional mechanisms that seek to protect individual autonomy through patient consent will be inadequate in a digitised ecosystem where processed data can travel near instantaneously across various nodes in the system and be combined, aggregated, or even re-identified. In this paper we explore the limitations of 'informed' consent that is sought either when data are collected or when they are ported across the system. We examine the merits and limitations of proposed alternatives like the fiduciary framework that imposes accountability on those

that use the data; privacy by design principles that rely on technological safeguards against abuse; or regulations. Our recommendations combine complementary approaches in light of the evolving jurisprudence in India and provide a generalisable framework for health data exchange that balances individual rights with advances in data science.

### **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 7 Aug 2021)

#### **Quantifying Covid19-vaccine location strategies for Germany**

*Vaccines are an important tool to limit the health and economic damage of the Covid-19 pandemic. Several vaccine candidates already provided promising effectiveness data, but it is crucial for an effective vac...*

Authors: Neele Leithäuser, Johanna Schneider, Sebastian Johann, Sven O. Krumke, Eva Schmidt, Manuel Streicher and Stefan Scholz

Citation: BMC Health Services Research 2021 21:780

Content type: Research

Published on: 7 August 2021

### **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 7 Aug 2021)

#### **Predictors of COVID-19 vaccine hesitancy among Egyptian healthcare workers: a cross-sectional study**

*Coronavirus disease 2019 (COVID-19) vaccination has raised concerns about vaccine hesitancy in general and COVID-19 vaccine hesitancy in particular. Understanding the factors driving the uncertainty regarding ...*

Authors: Rehab H. El-Sokkary, Omnia S. El Seifi, Hebatallah M. Hassan, Eman M. Mortada, Maiada K. Hashem, Mohamed Rabie Mohamed Ali Gadelrab and Rehab M. Elsaied Tash

Citation: BMC Infectious Diseases 2021 21:762

Content type: Research

Published on: 5 August 2021

#### **School-based surveillance of acute infectious disease in children: a systematic review**

*Syndromic surveillance systems are an essential component of public health surveillance and can provide timely detection of infectious disease cases and outbreaks. Whilst surveillance systems are generally emb...*

Authors: A. L. Donaldson, J. L. Hardstaff, J. P. Harris, R. Vivancos and S. J. O'Brien

Citation: BMC Infectious Diseases 2021 21:744

Content type: Research article

Published on: 3 August 2021

### **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 7 Aug 2021)

## **Personalized and long-term electronic informed consent in clinical research: stakeholder views**

*The landscape of clinical research has evolved over the past decade. With technological advances, the practice of using electronic informed consent (eIC) has emerged. However, a number of challenges hinder the...*

Authors: Evelien De Sutter, Pascal Borry, David Geerts and Isabelle Huys

Citation: BMC Medical Ethics 2021 22:108

Content type: Research

Published on: 31 July 2021

## **Motivation to participate and experiences of the informed consent process for randomized clinical trials in emergency obstetric care in Uganda**

*Informed consent, whose goal is to assure that participants enter research voluntarily after disclosure of potential risks and benefits, may be impossible or impractical in emergency research. In low resource ...*

Authors: Dan Kabonge Kaye

Citation: BMC Medical Ethics 2021 22:104

Content type: Research article

Published on: 28 July 2021

## **A scoping review of considerations and practices for benefit sharing in biobanking**

*Despite the rapid global growth of biobanking over the last few decades, and their potential for the advancement of health research, considerations specific to the sharing of benefits that accrue from biobanks...*

Authors: Allan Sudoi, Jantina De Vries and Dorcas Kamuya

Citation: BMC Medical Ethics 2021 22:102

Content type: Research

Published on: 27 July 2021

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 7 Aug 2021)

## **Evaluation of the safety profile of COVID-19 vaccines: a rapid review**

*The rapid process of research and development and lack of follow-up time post-vaccination aroused great public concern about the safety profile of COVID-19 vaccine candidates. To provide comprehensive overview...*

Authors: Qianhui Wu, Matthew Z. Dudley, Xinghui Chen, Xufang Bai, Kaige Dong, Tingyu Zhuang, Daniel Salmon and Hongjie Yu

Citation: BMC Medicine 2021 19:173

Content type: Research article

Published on: 28 July 2021

## **BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 7 Aug 2021)

[No new digest content identified]

## **BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 7 Aug 2021)

### **Onset of effects of non-pharmaceutical interventions on COVID-19 infection rates in 176 countries**

*During the initial phase of the global COVID-19 outbreak, most countries responded with non-pharmaceutical interventions (NPIs). In this study we investigate the general effectiveness of these NPIs, how long d...*

Authors: Ingo W. Nader, Elisabeth L. Zeilinger, Dana Jomar and Clemens Zauchner

Citation: BMC Public Health 2021 21:1472

Content type: Research article

Published on: 28 July 2021

### **Sexual behaviour, human papillomavirus and its vaccine: a qualitative study of adolescents and parents in Andalusia**

*Human papillomavirus (HPV) is one of the most common sexually transmitted infections and can be prevented by vaccination. The purpose of this study is to gain a better understanding, by analysing interview res...*

Authors: María González-Cano, Francisco Garrido-Peña, Eugenia Gil-Garcia, Marta Lima-Serrano and María Dolores Cano-Caballero

Citation: BMC Public Health 2021 21:1476

Content type: Research article

Published on: 28 July 2021

### **Factors influencing childhood immunisation uptake in Africa: a systematic review**

*Vaccine preventable diseases are still the most common cause of childhood mortality, with an estimated 3 million deaths every year, mainly in Africa and Asia. An estimate of 29% deaths among children aged 1–59...*

Authors: Abubakar Nasiru Galadima, Nor Afiah Mohd Zulkefli, Salmiah Md Said and Norliza Ahmad

Citation: BMC Public Health 2021 21:1475

Content type: Research article

Published on: 28 July 2021

## **BMC Research Notes**

<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 7 Aug 2021)

[No new digest content identified]

## **BMJ Evidence-Based Medicine**

August 2021 - Volume 26 - 4

<https://ebm.bmjjournals.org/content/26/4>

*Evidence synthesis*

**An evidence map of randomised controlled trials evaluating genetic therapies** (10 November, 2020)

*Genetic therapies replace or inactivate disease-causing genes or introduce new or modified genes. These therapies have the potential to cure in a single application rather than treating symptoms through repeated administrations. This evidence map provides a broad overview of the genetic therapies that have been evaluated in randomised controlled trials (RCTs) for efficacy and safety.* Eric A. Apaydin, Andrea S. Richardson, Sangita Baxi, Jerry Vockley, Olamigoke Akinniranye, Rachel Ross, Jody Larkin, Aneesa Motala, Gulrez Azhar, Susanne Hempel

## **BMJ Open**

August 2021 - Volume 11 - 8

<https://bmjopen.bmj.com/content/11/8>

### **Original research: Correlates of intended COVID-19 vaccine acceptance across time and countries: results from a series of cross-sectional surveys** (2 August, 2021)

John R Kerr, Claudia R Schneider, Gabriel Recchia, Sarah Dryhurst, Ullrika Sahlin, Carole Dufouil, Pierre Arwidson, Alexandra LJ Freeman, Sander van der Linden

## **Bulletin of the World Health Organization**

Volume 99, Number 7, July 2021, 477-540

<https://www.ncbi.nlm.nih.gov/pmc/issues/384766/>

[Reviewed earlier]

## **Cell**

Aug 05, 2021 Volume 184 Issue 16 p4107-4372

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

## **Child Care, Health and Development**

Volume 47, Issue 5 Pages: 575-731 September 2021

<https://onlinelibrary.wiley.com/toc/13652214/current>

[New issue; No digest content identified]

## **Clinical Pharmacology & Therapeutics**

Volume 110, Issue 2 Pages: 263-518 August 2021

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

### *Reviews*

Free Access

### **Collaborative Platform Trials to Fight COVID-19: Methodological and Regulatory Considerations for a Better Societal Outcome**

Olivier Collignon, Carl-Fredrik Burman, Martin Posch, Anja Schiel

Pages: 311-320

First Published: 28 January 2021

### *Abstract*

For the development of coronavirus disease 2019 (COVID-19) drugs during the ongoing pandemic, speed is of essence whereas quality of evidence is of paramount importance. Although thousands of

COVID-19 trials were rapidly started, many are unlikely to provide robust statistical evidence and meet regulatory standards (e.g., because of lack of randomization or insufficient power). This has led to an inefficient use of time and resources. With more coordination, the sheer number of patients in these trials might have generated convincing data for several investigational treatments. Collaborative platform trials, comparing several drugs to a shared control arm, are an attractive solution. Those trials can utilize a variety of adaptive design features in order to accelerate the finding of life-saving treatments. In this paper, we discuss several possible designs, illustrate them via simulations, and also discuss challenges, such as the heterogeneity of the target population, time-varying standard of care, and the potentially high number of false hypothesis rejections in phase II and phase III trials. We provide corresponding regulatory perspectives on approval and reimbursement, and note that the optimal design of a platform trial will differ with our societal objective and by stakeholder. Hasty approvals may delay the development of better alternatives, whereas searching relentlessly for the single most efficacious treatment may indirectly diminish the number of lives saved as time is lost. We point out the need for incentivizing developers to participate in collaborative evidence-generation initiatives when a positive return on investment is not met.

### **Clinical Therapeutics**

Volume 43 Issue 4 p651-792

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 18 Issue 4, August 2021

<https://journals.sagepub.com/toc/ctja/18/4>

[Reviewed earlier]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 7 Aug 2021]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 106 July 2021

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/106/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 4, Issue 3 / June 2021

<https://www.liebertpub.com/toc/crispr/4/3>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 9, issue 2, June 2021

<https://link.springer.com/journal/40142/volumes-and-issues/9-2>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

August 2021 - Volume 34 - Issue 4

<https://journals.lww.com/co-infectiousdiseases/pages/currrenttoc.aspx>

*INFECTIONS OF THE IMMUNOCOMPROMISED HOST*

#### **[Coronavirus disease 2019 vaccination in transplant recipients](#)**

Eberhardt, Christiane S.; Balletto, Elisa; Cornberg, Markus; More

Current Opinion in Infectious Diseases. 34(4):275-287, August 2021.

### **Current Protocols in Human Genetics**

Volume 108, Issue 1 December 2020

<https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current>

[Reviewed earlier]

### **Developing World Bioethics**

Volume 21, Issue 2 June 2021

<https://onlinelibrary.wiley.com/toc/14718847/current>

#### ***Special Issue: Conscientious objection to termination of pregnancy in the global south: legal and ethical challenges***

Issue Edited by: Anita Kleinsmidt

### **Development in Practice**

Volume 31, Issue 4, 2021

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 15 - Issue 2 - April 2021

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 45, Issue 3 Pages: 499-737 July 2021

<https://onlinelibrary.wiley.com/toc/14677717/current>

[Reviewed earlier]

### **EMBO Reports**

Volume 22 Issue 8 4 August 2021  
<https://www.embopress.org/toc/14693178/current>  
[New issue; No digest content identified]

### **Emerging Infectious Diseases**

Volume 27, Number 7—July 2021  
<http://wwwnc.cdc.gov/eid/>  
[Reviewed earlier]

### **Epidemics**

Volume 35 June 2021  
<https://www.sciencedirect.com/journal/epidemics/vol/35/suppl/C>  
[Reviewed earlier]

### **Epidemiology and Infection**

Volume 149 - 2021  
<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>  
[Reviewed earlier]

### **Ethics & Human Research**

Volume 43, Issue 4 Pages: 1-44 July–August 2021  
<https://onlinelibrary.wiley.com/toc/25782363/current>  
[Reviewed earlier]

### **The European Journal of Public Health**

SUPPLEMENT - Volume 31, Issue Supplement\_1, July 2021  
[https://academic.oup.com/eurpub/issue/31/Supplement\\_1](https://academic.oup.com/eurpub/issue/31/Supplement_1)

#### ***Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders' Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions***

Mental illness represents an enormous personal, social and societal burden for European citizens<sup>1</sup> calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,<sup>2</sup> and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications ('eHealth<sup>3</sup> and 'm-Health<sup>4</sup>) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders<sup>5,6</sup> and meta-analyses show effect sizes similar to face-to-face interventions.<sup>7</sup>

### **Expert Review of Vaccines**

Vol 20 (4) 2021  
<https://www.tandfonline.com/toc/ierv20/current>  
[Reviewed earlier]

## **Forum for Development Studies**

Volume 48, 2021 - Issue 2

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

## **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 7 Aug 2021]

*Method Article metrics AWAITING PEER REVIEW*

[\*\*Looking in the medicine cabinet: methods for using real-world data to assess the impact of measles, mumps and rubella \(MMR\) and recombinant adjuvanted varicella-zoster vaccines on coronavirus disease 2019 \(COVID-19\) prevention and case fatality\*\*](#) [version 1; peer review: awaiting peer review]

Douglas McNair, Hao Hu, Casey Selwyn

Peer Reviewers Invited

PUBLISHED 30 Jul 2021

*Open Letter metrics AWAITING PEER REVIEW*

[\*\*How modelling can help steer the course set by the World Health Organization 2021-2030 roadmap on neglected tropical diseases\*\*](#) [version 1; peer review: awaiting peer review]

Jessica Clark, Wilma A. Stolk, María-Gloria Basáñez, Luc E. Coffeng, Zulma M. Cucunubá, Matthew A. Dixon, Louise Dyson, Katie Hampson, Michael Marks, Graham F. Medley, Timothy M. Pollington, Joaquin M. Prada, Kat S. Rock, Henrik Salje, Jaspreet Toor, T. Déirdre Hollingsworth

Peer Reviewers Invited

Funders

Bill and Melinda Gates Foundation

UK Foreign, Commonwealth & Development Office

European and Developing Countries Clinical Trials Partnership (EDCTP2) programme

MRC Centre for Global Infectious Disease Analysis

UK Department for International Development

UK Medical Research Council

PUBLISHED 27 Jul 2021

## **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 7 Aug 2021]

[Reviewed earlier]

## **Global Health Action**

Volume 14, Issue 1 (2021)

<https://www.tandfonline.com/toc/zgha20/current?nav=tocList>

[Reviewed earlier]

## **Global Health: Science and Practice (GHSP)**

Vol. 9, No. 2 June 30, 2021

<http://www.ghspjournal.org/content/current>

[Reviewed earlier]

## **Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>

[Accessed 7 Aug 2021]

[No new digest content identified]

## **Global Public Health**

Volume 16, Issue 8-9 (2021)

<http://www.tandfonline.com/toc/rgph20/current>

### ***Politics and pandemics***

This Special Issue of Global Public Health on Politics & Pandemics brings together 26 articles and commentaries that address diverse aspects of the politics of COVID-19 and related issues. These papers are grouped together in six topical areas: theories and politics of global health, health systems and policies, country responses, social inequalities, social responses, and the politics of science and technology. The goal of the Special Issue is to give readers a sense of the range of topics that have been a focus for research in relation to the COVID-19 pandemic and to provide diverse examples of how research and analysis on the political dimensions of the pandemic can contribute to confronting the COVID-19 crisis.

#### *Article*

### **[Global justice and the COVID-19 vaccine: Limitations of the public goods framework](#)**

Nivedita Saksena

Pages: 1512-1521

Published online: 25 Mar 2021

#### *ABSTRACT*

As vaccines for COVID-19 were first being approved for use, there were widespread calls for it to be assigned a 'global public good'. However, allocating the COVID-19 vaccine globally poses a novel challenge of redistribution, one that cannot be effectively undertaken using current mechanisms for the dispensation of aid. An examination of the origins and implicit logic of global public goods theory shows that it would not be effective as a framework in this context. I argue that while it is a useful rhetorical tool to underscore the need for global access, it fails to account for concerns arising out of structural inequities between countries in the Global South and North. In addition to being ill-defined, the phrase encodes a neoliberal logic – one that prioritises the protection of private capital over democratic claims of redistribution and social justice. To ensure global access, our attention must be focussed instead on explicitly accounting for inequities, securing access for countries in the Global South and addressing the norm-setting powers of pharmaceutical companies.

## **Globalization and Health**

<http://www.globalizationandhealth.com/>

[Accessed 7 Aug 2021]

## **Global infectious disease research collaborations in crises: building capacity and inclusivity through cooperation**

*The initial research requirements in pandemics are predictable. But how is it possible to study a disease that is so quickly spreading and to rapidly use that research to inform control and treatment?*

Authors: Jonathon P. Fanning, Srinivas Murthy, Nchafatso G. Obonyo, J. Kenneth Baillie, Steve Webb, Heidi J. Dalton and John F. Fraser

Citation: Globalization and Health 2021 17:84

Content type: Commentary

Published on: 26 July 2021

## **Health Affairs**

Vol. 40, No. 7 July 2021

<https://www.healthaffairs.org/toc/hlthaff/current>

### ***July 2021 / Borders, Immigrants & Health***

About one in seven residents of the US is an immigrant, and about fifteen million people live within 100 kilometers of the US-Mexico border. Disparities in health status exist between people born in the US and those who have immigrated. Immigration policy has been contentious throughout US history, and current policies in the US and Mexico have significant effects on the health and well-being of tens of millions of people. This thematic issue of *Health Affairs* focuses on immigrants and borders. The overview article by Arturo Vargas Bustamante and coauthors describes a range of health policy issues raised by the continuously shifting demography of US immigrants.

## **Health and Human Rights**

Volume 22, Issue 1, June 2020

<https://www.hhrjournal.org/volume-22-issue-1-june-2020/>

### ***Special Section: Mental Health and Human Rights***

[Reviewed earlier]

## **Health Economics, Policy and Law**

Volume 16 - Issue 3 - July 2021

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

[Reviewed earlier]

## **Health Policy and Planning**

Volume 36, Issue 5, June 2021

<https://academic.oup.com/heapol/issue/36/5>

[Reviewed earlier]

## **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 7 Aug 2021]

[No new digest content identified]

**Human Gene Therapy**

Volume 32, Issue 13-14 / July 2021

<https://www.liebertpub.com/toc/hum/32/13-14>

[New issue; No digest content identified]

**Humanitarian Exchange Magazine**

Number 79, May 2021

<https://odihpn.org/magazine/inclusion-of-persons-with-disabilities-in-humanitarian-action-what-now/>

**Localisation and local humanitarian action**

by HPN October 2020

The theme of this edition of *Humanitarian Exchange* is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in 2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and decolonisation have also brought new momentum to critical reflections on where power, knowledge and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain between the rhetoric around humanitarian partnerships, funding and coordination and practices on the ground.

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 17, Issue 5, 2021

<https://www.tandfonline.com/toc/khvi20/current>

[Reviewed earlier]

**Infectious Agents and Cancer**

<http://www.infectagentscancer.com/content>

[Accessed 7 Aug 2021]

[No new digest content identified]

**Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 7 Aug 2021]

[No new digest content identified]

**International Health**

Volume 13, Issue 4, July 2021

<https://academic.oup.com/inthealth/issue/13/4>

[Reviewed earlier]

**International Human Rights Law Review**

Volume 10 (2021): Issue 1 (Jun 2021)

<https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml>

[Reviewed earlier]

**International Journal of Community Medicine and Public Health**

Vol 8, No 5 (2021) May 2021

<https://www.ijcmph.com/index.php/ijcmph/issue/view/76>

[Reviewed earlier]

**International Journal of Epidemiology**

Volume 50, Issue 3, June 2021

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

**International Journal of Human Rights in Healthcare**

Volume 14 Issue 1 2021

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1>

*Table of Contents*

[Reviewed earlier]

**International Journal of Infectious Diseases**

July 2021 Volume 108 p1-616

<https://www.ijidonline.com/current>

[Reviewed earlier]

**JAMA**

August 3, 2021, Vol 326, No. 5, Pages 373-450

<https://jamanetwork.com/journals/jama/currentissue>

*Viewpoint*

**Potential Benefits of Expanded COVID-19 Surveillance in the US**

David R. Holtgrave, PhD; Sten H. Vermund, MD, PhD; Leana S. Wen, MD, MSc

free access

JAMA. 2021;326(5):381-382. doi:10.1001/jama.2021.11211

This Viewpoint proposes several important areas of surveillance expansion by US public health agencies and other institutions for COVID-19 testing, vaccination, infection, and mortality rates.

**JAMA Network**

**COVID-19 Update August 7, 2021**

*These articles on COVID-19 were published across the JAMA Network in the last week.*

**JAMA Pediatrics**

August 2021, Vol 175, No. 8, Pages 766-876

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

[New issue; No digest content identified]

**JBI Evidence Synthesis**

August 2021 Volume 69 Issue 2 p181-356

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Adolescent Health**

July 2021 Volume 69 Issue 1 p1-180

<https://www.jahonline.org/current>

[New issue; No digest content identified]

**Journal of Artificial Intelligence Research**

Vol. 71 (2021)

<https://www.jair.org/index.php/jair>

[Reviewed earlier]

**Journal of Community Health**

Volume 46, issue 3, June 2021

<https://link.springer.com/journal/10900/volumes-and-issues/46-3>

[Reviewed earlier]

**Journal of Development Economics**

Volume 151 June 2021

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/151/suppl/C>

[Reviewed earlier]

**Journal of Empirical Research on Human Research Ethics**

Volume 16 Issue 3, July 2021

<http://journals.sagepub.com/toc/jre/current>

[Reviewed earlier]

**Journal of Epidemiology & Community Health**

July 2021 - Volume 75 - 7

<https://jech.bmj.com/content/75/7>

[New issue; No digest content identified]

**Journal of Evidence-Based Medicine**

Volume 14, Issue 2 Pages: 83-169 May 2021

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

**Journal of Global Ethics**

Volume 16, Issue 3, 2020

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 32, Number 2, May 2021 Supplement

<https://muse.jhu.edu/issue/44396>

*Table of Contents*

**Overview of the Issue**

Kevin B. Johnson, Tiffani J. Bright, Cheryl R. Clark

...The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.

This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care...

**Journal of Immigrant and Minority Health**

Volume 23, issue 3, June 2021

<https://link.springer.com/journal/10903/volumes-and-issues/23-3>

[Reviewed earlier]

**Journal of Immigrant & Refugee Studies**

Volume 19, 2021\_ Issue 2

<https://www.tandfonline.com/toc/wimm20/current>

[Reviewed earlier]

**Journal of Infectious Diseases**

Volume 224, Issue 2, 15 July 2021

<https://academic.oup.com/jid/issue/224/2>

[Reviewed earlier]

**Journal of Medical Ethics**

July 2021 - Volume 47 - 7

<http://jme.bmjjournals.org/content/current>

[Reviewed earlier]

**Journal of Patient-Centered Research and Reviews**

Volume 8, Issue 3 (2021)

<https://digitalrepository.aurorahealthcare.org/jpcrr/>

[Reviewed earlier]

**Journal of Pediatrics**

August 2021 Volume 235 p1-306

<http://www.jpeds.com/current>

[Reviewed earlier]

**Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 7 Aug 2021]

[No new digest content identified]

**Journal of Public Health Management & Practice**

July/August 2021 - Volume 27 - Issue 4

<https://jphmp.lww.com/jphmp/pages/currenttoc.aspx>

[Reviewed earlier]

**Journal of Public Health Policy**

Volume 42, issue 2, June 2021

<https://link.springer.com/journal/41271/volumes-and-issues/42-2>

[Reviewed earlier]

**Journal of Refugee & Global Health**

Volume 4, Issue 1 (2021)

<https://ir.library.louisville.edu/rgh/>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

August 2021 Volume 18 Issue 181

<https://royalsocietypublishing.org/toc/rsif/current>

[New issue; No digest content identified]

**Journal of Travel Medicine**

Volume 28, Issue 5, July 2021

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 95 Number 16 July 2021

<http://jvi.asm.org/content/current>

*Spotlight*

**Articles of Significant Interest In This Issue**

Poxviruses are exceptional in having a multicomponent entry-fusion complex (EFC) that is comprised of eleven conserved proteins embedded in the membrane of mature virions. Schin et al. (e00852-21) adapted the tripartite split green fluorescent protein complementation system to determine individual EFC protein contacts by proximity analysis within living cells. Previous EFC protein interactions were confirmed and new ones discovered and corroborated by additional methods. Most remarkable was the finding that the small, hydrophobic O3 protein interacted with each of the other EFC proteins, suggesting that multiple copies stabilize the complex within the viral membrane

**The Lancet**

Aug 07, 2021 Volume 398 Number 10299 p465-558, e9

<https://www.thelancet.com/journals/lancet/issue/current>

*Comment*

**Measuring and ensuring routine childhood vaccination coverage**

M Carolina Danovaro-Holliday, Katrina Kretsinger, Marta Gacic-Dobo

**Disruptions to childhood immunisation due to the COVID-19 pandemic**

Kaja Abbas, Vittal Mogasale

*Articles*

**Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1**

GBD 2020, Release 1, Vaccine Coverage Collaborators

*Open Access*

*Summary*

*Background*

Measuring routine childhood vaccination is crucial to inform global vaccine policies and programme implementation, and to track progress towards targets set by the Global Vaccine Action Plan (GVAP) and Immunization Agenda 2030. Robust estimates of routine vaccine coverage are needed to identify

past successes and persistent vulnerabilities. Drawing from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2020, Release 1, we did a systematic analysis of global, regional, and national vaccine coverage trends using a statistical framework, by vaccine and over time.

#### Methods

For this analysis we collated 55 326 country-specific, cohort-specific, year-specific, vaccine-specific, and dose-specific observations of routine childhood vaccination coverage between 1980 and 2019. Using spatiotemporal Gaussian process regression, we produced location-specific and year-specific estimates of 11 routine childhood vaccine coverage indicators for 204 countries and territories from 1980 to 2019, adjusting for biases in country-reported data and reflecting reported stockouts and supply disruptions. We analysed global and regional trends in coverage and numbers of zero-dose children (defined as those who never received a diphtheria-tetanus-pertussis [DTP] vaccine dose), progress towards GVAP targets, and the relationship between vaccine coverage and sociodemographic development.

#### Findings

By 2019, global coverage of third-dose DTP (DTP3; 81·6% [95% uncertainty interval 80·4–82·7]) more than doubled from levels estimated in 1980 (39·9% [37·5–42·1]), as did global coverage of the first-dose measles-containing vaccine (MCV1; from 38·5% [35·4–41·3] in 1980 to 83·6% [82·3–84·8] in 2019). Third-dose polio vaccine (Pol3) coverage also increased, from 42·6% (41·4–44·1) in 1980 to 79·8% (78·4–81·1) in 2019, and global coverage of newer vaccines increased rapidly between 2000 and 2019. The global number of zero-dose children fell by nearly 75% between 1980 and 2019, from 56·8 million (52·6–60·9) to 14·5 million (13·4–15·9). However, over the past decade, global vaccine coverage broadly plateaued; 94 countries and territories recorded decreasing DTP3 coverage since 2010. Only 11 countries and territories were estimated to have reached the national GVAP target of at least 90% coverage for all assessed vaccines in 2019.

#### Interpretation

After achieving large gains in childhood vaccine coverage worldwide, in much of the world this progress was stalled or reversed from 2010 to 2019. These findings underscore the importance of revisiting routine immunisation strategies and programmatic approaches, recentring service delivery around equity and underserved populations. Strengthening vaccine data and monitoring systems is crucial to these pursuits, now and through to 2030, to ensure that all children have access to, and can benefit from, lifesaving vaccines.

#### Funding

Bill & Melinda Gates Foundation.

### **Estimating global and regional disruptions to routine childhood vaccine coverage during the COVID-19 pandemic in 2020: a modelling study**

Kate Causey, et al

Open Access

#### *Summary*

#### *Background*

The COVID-19 pandemic and efforts to reduce SARS-CoV-2 transmission substantially affected health services worldwide. To better understand the impact of the pandemic on childhood routine immunisation, we estimated disruptions in vaccine coverage associated with the pandemic in 2020, globally and by Global Burden of Disease (GBD) super-region.

#### *Methods*

For this analysis we used a two-step hierarchical random spline modelling approach to estimate global and regional disruptions to routine immunisation using administrative data and reports from electronic immunisation systems, with mobility data as a model input. Paired with estimates of vaccine coverage

expected in the absence of COVID-19, which were derived from vaccine coverage models from GBD 2020, Release 1 (GBD 2020 R1), we estimated the number of children who missed routinely delivered doses of the third-dose diphtheria-tetanus-pertussis (DTP3) vaccine and first-dose measles-containing vaccine (MCV1) in 2020.

#### Findings

Globally, in 2020, estimated vaccine coverage was 76·7% (95% uncertainty interval 74·3–78·6) for DTP3 and 78·9% (74·8–81·9) for MCV1, representing relative reductions of 7·7% (6·0–10·1) for DTP3 and 7·9% (5·2–11·7) for MCV1, compared to expected doses delivered in the absence of the COVID-19 pandemic. From January to December, 2020, we estimated that 30·0 million (27·6–33·1) children missed doses of DTP3 and 27·2 million (23·4–32·5) children missed MCV1 doses. Compared to expected gaps in coverage for eligible children in 2020, these estimates represented an additional 8·5 million (6·5–11·6) children not routinely vaccinated with DTP3 and an additional 8·9 million (5·7–13·7) children not routinely vaccinated with MCV1 attributable to the COVID-19 pandemic. Globally, monthly disruptions were highest in April, 2020, across all GBD super-regions, with 4·6 million (4·0–5·4) children missing doses of DTP3 and 4·4 million (3·7–5·2) children missing doses of MCV1. Every GBD super-region saw reductions in vaccine coverage in March and April, with the most severe annual impacts in north Africa and the Middle East, south Asia, and Latin America and the Caribbean. We estimated the lowest annual reductions in vaccine delivery in sub-Saharan Africa, where disruptions remained minimal throughout the year. For some super-regions, including southeast Asia, east Asia, and Oceania for both DTP3 and MCV1, the high-income super-region for DTP3, and south Asia for MCV1, estimates suggest that monthly doses were delivered at or above expected levels during the second half of 2020.

#### Interpretation

Routine immunisation services faced stark challenges in 2020, with the COVID-19 pandemic causing the most widespread and largest global disruption in recent history. Although the latest coverage trajectories point towards recovery in some regions, a combination of lagging catch-up immunisation services, continued SARS-CoV-2 transmission, and persistent gaps in vaccine coverage before the pandemic still left millions of children under-vaccinated or unvaccinated against preventable diseases at the end of 2020, and these gaps are likely to extend throughout 2021. Strengthening routine immunisation data systems and efforts to target resources and outreach will be essential to minimise the risk of vaccine-preventable disease outbreaks, reach children who missed routine vaccine doses during the pandemic, and accelerate progress towards higher and more equitable vaccination coverage over the next decade.

#### Funding

Bill & Melinda Gates Foundation.

### **The Lancet Child & Adolescent Health**

Jul 2021 Volume 5 Number 7 p459-530

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

### **Lancet Digital Health**

Jul 2021 Volume 3 Number 7 e408-e461

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

**Lancet Global Health**

Jul 2021 Volume 9 Number 7 e880-e1027

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

**Lancet Infectious Diseases**

Jul 2021 Volume 21 Number 7 p889-1050, e182-e207

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

**Lancet Public Health**

Jun 2021 Volume 6 Number 6 e346-e433

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

**Lancet Respiratory Medicine**

Jul 2021 Volume 9 Number 7 p673-802, e56-e68

<https://www.thelancet.com/journals/lanres/issue/current>

[Reviewed earlier]

**Maternal and Child Health Journal**

Volume 25, issue 6, June 2021

<https://link.springer.com/journal/10995/volumes-and-issues/25-6>

[Reviewed earlier]

**Medical Decision Making (MDM)**

Volume 41 Issue 5, July 2021

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

**The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 99, Issue 2 Pages: 329-599 June 2021

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

**Nature**

Volume 596 Issue 7870, 5 August 2021

<https://www.nature.com/nature/volumes/596/issues/7870>

*World View* | 03 August 2021

## **Cash payments in Africa could boost vaccine uptake**

When doses finally arrive, use cash incentives to overcome hesitancy.

Rabah Arezki

*Book Review | 02 August 2021*

## **The COVID vaccine makers tell all**

A book from the Oxford–AstraZeneca team, and a documentary, go behind the scenes in the race to vaccinate the world.

Heidi Ledford

## **Nature Biotechnology**

Volume 39 Issue 7, July 2021

<https://www.nature.com/nbt/volumes/39/issues/7>

[Reviewed earlier]

## **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 7 Aug 2021)

[No new digest content identified]

## **Nature Genetics**

Volume 53 Issue 7, July 2021

<https://www.nature.com/ng/volumes/53/issues/7>

[Reviewed earlier]

## **Nature Human Behaviour**

Volume 5 Issue 6, June 2021

<https://www.nature.com/nathumbehav/volumes/5/issues/6>

[Reviewed earlier]

## **Nature Medicine**

Volume 27 Issue 7, July 2021

<https://www.nature.com/nm/volumes/27/issues/7>

[Reviewed earlier]

## **Nature Reviews Genetics**

Volume 22 Issue 7, July 2021

<https://www.nature.com/nrg/volumes/22/issues/7>

[Reviewed earlier]

## **Nature Reviews Immunology**

Volume 21 Issue 7, July 2021  
<https://www.nature.com/nri/volumes/21/issues/7>  
[Reviewed earlier]

**Nature Reviews Drug Discovery**  
Volume 20 Issue 7, July 2021  
<https://www.nature.com/nrd/volumes/20/issues/7>  
[Reviewed earlier]

**New England Journal of Medicine**  
August 5, 2021 Vol. 385 No. 6  
<http://www.nejm.org/toc/nejm/medical-journal>  
*Perspective*  
[\*\*Contact Tracing for Covid-19 — A Digital Inoculation against Future Pandemics\*\*](#)  
J. O'Connell and D.T. O'Keeffe

**Pediatrics**  
August 01, 2021; Volume 148, Issue 2  
<https://pediatrics.aappublications.org/>  
*Articles*  
[\*\*Patient Portal Reminders for Pediatric Influenza Vaccinations: A Randomized Clinical Trial\*\*](#)  
Carlos Lerner, Christina Albertin, Alejandra Casillas, O. Kenrik Duru, Michael K. Ong, Sitaram Vangala, Sharon Humiston, Sharon Evans, Michael Sloyan, Craig R. Fox, Jonathan E. Bogard, Sarah Friedman, Peter G. Szilagyi  
Pediatrics, Aug 2021, 148 (2) e2020048413

*From the American Academy of Pediatrics*  
*Open Access*  
[\*\*COVID-19 Vaccines in Children and Adolescents\*\*](#)  
Committee on Infectious Diseases  
Pediatrics, Aug 2021, 148 (2) e2021052336

**PharmacoEconomics**  
Volume 39, issue 7, July 2021  
<https://link.springer.com/journal/40273/volumes-and-issues/39-7>  
[New issue; No digest content identified]

**PLoS Biology**  
<https://journals.plos.org/plosbiology/>  
(Accessed 7 Aug 2021)  
[\*\*Educating the future generation of researchers: A cross-disciplinary survey of trends in analysis methods\*\*](#)  
Taylor Bolt, Jason S. Nomi, Danilo Bzdok, Lucina Q. Uddin

**PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 7 Aug 2021)

[No new digest content identified]

**PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 7 Aug 2021)

**[Levels of pneumococcal conjugate vaccine coverage and indirect protection against invasive pneumococcal disease and pneumonia hospitalisations in Australia: An observational study](#)**

Jocelyn Chan, Heather F. Gidding, Christopher C. Blyth, Parveen Fathima, Sanjay Jayasinghe, Peter B. McIntyre, Hannah C. Moore, Kim Mulholland, Cattram D. Nguyen, Ross Andrews, Fiona M. Russell

Research Article | published 03 Aug 2021 PLOS Medicine

<https://doi.org/10.1371/journal.pmed.1003733>

**PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

*Research Article*

**[Cost-effectiveness of dengue vaccination in Puerto Rico](#)**

Guido España, Andrew J. Leidner, Stephen H. Waterman, T. Alex Perkins

| published 26 Jul 2021 PLOS Neglected Tropical Diseases

<https://doi.org/10.1371/journal.pntd.0009606>

**PLoS One**

<http://www.plosone.org/>

[Accessed 7 Aug 2021]

**[Validation of a redesigned pan-poliovirus assay and real-time PCR platforms for the global poliovirus laboratory network](#)**

Hong Sun, Chelsea Harrington, Nancy Gerloff, Mark Mandelbaum, Stacey Jeffries-Miles, Lea Necitas G. Apostol, Ma. Anne-Lesley D. Valencia, Shahzad Shaukat, Mehar Angez, Deepa K. Sharma, Uma P. Nalavade, Shailesh D. Pawar, Elisabeth Pukuta Simbu, Seta Andriamamonjy, Richter Razafindratsimandresy, Everardo Vega

Research Article | published 06 Aug 2021 PLOS ONE

<https://doi.org/10.1371/journal.pone.0255795>

**[Rotavirus A infection in pre- and post-vaccine period: Risk factors, genotypes distribution by vaccination status and age of children in Nampula Province, Northern Mozambique \(2015-2019\)](#)**

Assucênia Chissaque, Adilson Fernando Loforte Bauhofer, Idalécia Cossa-Moiane, Ezequias Sitoe, Benilde Munlela, Eva Dora João, Jerônimo S. Langa, Jorfélia José Chilaúle, Simone Salvador Boene, Marta Cassocera, Esperança Lourenço Guimarães, Timothy A. Kellogg, Luzia Gonçalves, Nilsa de Deus  
Research Article | published 06 Aug 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0255720>

**[COVID-19 vaccine access and attitudes among people experiencing homelessness from pilot mobile phone survey in Los Angeles, CA](#)**

Randall Kuhn, Benjamin Henwood, Alexander Lawton, Mary Kleva, Karthik Murali, Coley King, Lillian Gelberg  
Research Article | published 30 Jul 2021 PLOS ONE  
<https://doi.org/10.1371/journal.pone.0255246>

**PLoS Pathogens**

<http://journals.plos.org/plospathogens/>  
[Accessed 7 Aug 2021]  
[No new digest content identified]

**PNAS - Proceedings of the National Academy of Sciences of the United States of America**

July 27, 2021; vol. 118 no. 30  
<https://www.pnas.org/content/118/30>

*Microbiology*

**[Design and proof of concept for targeted phage-based COVID-19 vaccination strategies with a streamlined cold-free supply chain](#)**

Daniela I. Staquicini, Fenny H. F. Tang, Christopher Markosian, Virginia J. Yao, Fernanda I. Staquicini, Esteban Dodero-Rojas, Vinícius G. Contessoto, Deodate Davis, Paul O'Brien, Nazia Habib, Tracey L. Smith, Natalie Bruiners, Richard L. Sidman, Maria L. Gennaro, Edmund C. Lattime, Steven K. Libutti, Paul C. Whitford, Stephen K. Burley, José N. Onuchic, Wadih Arap, and Renata Pasqualini  
PNAS July 27, 2021 118 (30) e2105739118; <https://doi.org/10.1073/pnas.2105739118>

**Prehospital & Disaster Medicine**

Volume 36 - Issue 4 - August 2021  
<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>  
[New issue; No digest content identified]

**Preventive Medicine**

Volume 148 July 2021  
<https://www.sciencedirect.com/journal/preventive-medicine/vol/148/suppl/C>  
[New issue; No digest content identified]

**Proceedings of the Royal Society B**

28 July 2021 Volume 288 Issue 1955

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

### **Public Health**

Volume 195 Pages 1-160 (June 2021)

<https://www.sciencedirect.com/journal/public-health/vol/195/suppl/C>

[Reviewed earlier]

### **Public Health Ethics**

Volume 14, Issue 1, April 2021

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

### **Public Health Reports**

Volume 136 Issue 4, July/August 2021

<https://journals.sagepub.com/toc/phrg/136/4>

[Reviewed earlier]

### **Qualitative Health Research**

Volume 31 Issue 8, July 2021

<http://qhr.sagepub.com/content/current>

[Reviewed earlier]

### **Research Ethics**

Volume 17 Issue 3, July 2021

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 7 Aug 2021]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health**

**(RPSP/PAJPH)**

<https://www.paho.org/journal/en>

*Selected Articles*

[No new digest content identified]

### **Risk Analysis**

Volume 41, Issue 6 Pages: 843-1045 June 2021  
<https://onlinelibrary.wiley.com/toc/15396924/current>  
[Reviewed earlier]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>  
[Accessed 7 Aug 2021]  
[No new digest content identified]

### **Science**

06 August 2021 Vol 373, Issue 6555  
<http://www.sciencemag.org/current.dtl>

*In Depth*

#### **[Taliban's rise puts polio eradication in danger](#)**

By Leslie Roberts  
Science06 Aug 2021 : 605-606 Restricted Access

*U.S. departure from Afghanistan raises questions about future of vaccination drives.*

*Summary*

The U.S. troop withdrawal from Afghanistan is imperiling the 3-decade global quest to eradicate polio. The Taliban, which now controls large swaths of the country, has blocked house-to-house polio vaccination in areas under its reign the past 3 years, putting up to 3 million children out of reach of the campaign. The Taliban may well wrest complete control from the Afghan government—which supports the eradication campaign—after U.S. forces are gone. But some inside and outside the Global Polio Eradication Initiative say a clear resolution to the conflict, regardless of who prevails, may actually aid eradication efforts. They hope the campaign will be able to work with the Taliban to keep vaccinations going if it consolidates power.

### **Science Translational Medicine**

04 August 2021 Vol 13, Issue 605  
<https://stm.sciencemag.org/>  
[New issue; No digest content identified]

### **Social Science & Medicine**

Volume 278 June 2021  
<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/278/suppl/C>  
[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>  
[Accessed 7 Aug 2021]  
[No new digest content identified]

## **Theoretical Medicine and Bioethics**

Volume 41, issue 5-6, December 2020

<https://link.springer.com/journal/11017/volumes-and-issues/41-5>

[Reviewed earlier]

## **Travel Medicine and Infectious Diseases**

Volume 41 May–June 2021

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/41/suppl/C>

[Reviewed earlier]

## **Tropical Medicine & International Health**

Volume 26, Issue 7 Pages: i-iv, 715-837 July 2021

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

## **Vaccine**

Volume 39, Issue 30 Pages 4013-4238 (5 July 2021)

<https://www.sciencedirect.com/journal/vaccine/vol/39/issue/30>

*Conference info Abstract only*

### **[Evaluation of post-introduction COVID-19 vaccine effectiveness: Summary of interim guidance of the World Health Organization](#)**

Minal K. Patel, Isabel Bergeri, Joseph S. Bresee, Benjamin J. Cowling, ... Daniel R. Feikin

Pages 4013-4024

*Discussion Full text access*

### **[A new group at increased risk of a SARS-CoV-2 infection emerges: The recently vaccinated](#)**

Sebastian Hoehl, Sandra Ciesek, Jürgen Graf, Sabine Wicker

Pages 4025-4026

*Discussion Full text access*

### **[One size does not fit all: Lessons from Israel's Covid-19 vaccination drive and hesitancy](#)**

Aviad Raz, Yael Keshet, Ariela Popper-Giveon, Maha Sabbah Karkabi

Pages 4027-4028

*Discussion No access*

### **[Public trust on regulatory decisions: The European Medicines Agency and the AstraZeneca COVID-19 vaccine label](#)**

Rafael Dal-Ré, Odile Launay

Pages 4029-4031

*Review article Abstract only*

### **[Charting mandatory childhood vaccination policies worldwide](#)**

Samantha Vanderslott, Tatjana Marks

Pages 4054-4062

Research article Open access

**[Cost effectiveness of typhoid vaccination in India](#)**

Akashdeep Singh Chauhan, Isha Kapoor, Saroj Kumar Rana, Dilesh Kumar, ... Shankar Prinja

Pages 4089-4098

Research article Open access

**[School-based HPV vaccination positively impacts parents' attitudes toward adolescent vaccination](#)**

Cristyn Davies, Tanya Stoney, Heidi Hutton, Adriana Parrella, ... S. Rachel Skinner

Pages 4190-4198

**Value in Health**

July 2021 Volume 24 Issue 7 p917-1088

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

\* \* \* \*

***[Think Tanks et al](#)***

**Brookings** [to 7 Aug 2021]

<http://www.brookings.edu/>

*FixGov*

**[Vaccine mandates are more popular than you think](#)**

William A. Galston

Thursday, August 5, 2021

*Interactive*

**[COVID-19 vaccination efforts in the Middle East and North Africa](#)**

Paul Dyer, Isaac Schäider, and Andrew Letzkus

Tuesday, August 3, 2021

**Center for Global Development** [to 7 Aug 2021]

<http://www.cgdev.org/page/press-center>

*Publications*

**[Better Together: Exploring the Role of Pooled Procurement in Improving Access to Medicines amid COVID-19](#)**

August 2, 2021

Access to safe, effective, and affordable essential medicines is an integral global health goal, and all the more important during a public health emergency like COVID-19. Supply chain inefficiencies, procurement capacity constraints, and financial difficulties impede access to affordable, quality medicines; crises exacerbate these issues.

Julia Kaufman, Morgan Pincombe and Javier Guzman

## **The US Is Losing the Global War Against COVID-19—And That Is a National Security Issue**

July 28, 2021

"The fight against COVID-19 is a global war but policymakers are not behaving accordingly. As a result... the scars will haunt our international relations for years to come."

Masood Ahmed

**Chatham House** [to 7 Aug 2021]

<https://www.chathamhouse.org/>

*Accessed 7 Aug 2021*

[No new digest content identified]

**CSIS**

<https://www.csis.org/>

*Accessed 7 Aug 2021*

*Podcast Episode*

**Chris Murray, IHME: "A Very Awkward Situation"**

August 6, 2021 | By [J. Stephen Morrison](#)

Chris Murray, director of IHME, joined our podcast once again, at this major moment of reset of expectations – of our ability to control the pandemic, of policy decisions, data gaps, political attitudes and behavior, hitting the wall of hesitancy and refusal to vaccinate, and public confusion. We cover the full gamut: the forecast for the fall surge, missteps on masking, the need for greater transparency in data, and how much room exists to overcome resistance to vaccines.

*Transcript*

**A Conversation with Dr. Anthony Fauci on the Antiviral Program for Pandemics**

August 3, 2021

*Report*

**U.S. Emergency Plan for Global Covid-19 Relief: Urgent Action to End the Pandemic**

**Globally and Accelerate U.S. Recovery and Security**

August 3, 2021

*Podcast Episode*

**China's Global Response to the COVID-19 Pandemic: A Conversation with Dr. Yanzhong Huang**

August 3, 2021 | By [Bonny Lin](#)

**Kaiser Family Foundation**

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

August 4, 2021 *News Release*

**Most Unvaccinated Adults Don't Believe the Vaccines are Very Effective and See the Vaccines as a Greater Health Risk than COVID-19 Itself**

Vaccinated Adults Are Nearly Twice as Likely as Unvaccinated Ones to Worry that New Variants Like Delta Will Worsen the Pandemic Nationally and Locally As public health officials struggle to boost

vaccination rates nationally, the latest KFF COVID-19 Vaccine Monitor reports that a narrow majority (53%) of unvaccinated adults believe...

August 2, 2021 *News Release*

### **Once Common, COVID-19 Deaths in Long-Term Care Were Rare across Most States in June**

Early in the COVID-19 pandemic, residents and staff at nursing homes and other long-term care facilities accounted for a huge share of COVID deaths, but a new KFF analysis finds that they were relatively rare events across the country in June. The analysis finds that 13 states and the District...

July 30, 2021 *News Release*

### **COVID-19 Vaccine Breakthrough Cases Are Extremely Rare, According to KFF State Data Analysis**

As COVID-19 cases increase along with spread of the more transmissible Delta variant, the effectiveness of COVID-19 vaccines continues to be an important topic. A new KFF analysis looks at COVID-19 vaccine “breakthrough cases,” when fully vaccinated individuals become infected, as well as hospitalizations and deaths, to see which states...

\* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by-nc/3.0/>). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \*